TW201540713A - Piperidine derivatives as orexin receptor antagonist - Google Patents

Abstract

The present invention discloses a series of piperidine derivatives as orexin receptor antagonists and compositions thereof, and relates to the application thereof in preparing medications for the treatment of insomnia, chronic obstructive pulmonary disease, obstructive sleep apnea, hypersomnia, anxiety, obsessive-compulsive disorder, panic attack, nicotine addiction, or binge eating disorder.

Description

Acridine derivative as an appetite hormone receptor antagonist

The present invention relates to acridine derivatives and their compositions as appetite hormone receptor antagonists, and to the preparation thereof for the treatment of insomnia, chronic obstructive pulmonary disease, obstructive sleep apnea, lethargy, anxiety, coercion, panic, nicotine dependence or The use of drugs in the application of dietary disorders disorders.

The appetite hormone ( orexin) includes two neuropeptides produced in the hypothalamus: appetite hormone A (OX-A) (33 amino acid peptide) and appetite hormone B (OX-B) (28 amino acid peptide) ( Sakurai T. et al., Cell, 1998, 92, 573-585). Appetite hormones have been found to stimulate food consumption in rats, suggesting that these peptides have physiological roles as mediators in a central feedback mechanism that regulates feeding behavior (Sakurai T. et al., Cell, 1998, 92, 573-585). ). Appetite hormones can modulate the state of sleep and insomnia, potentially suggesting new ways to treat patients with narcolepsy or insomnia (Chemelli R. M. et al., Cell, 1999, 98, 437-451). Appetite hormones also play a role in arousal, motivation, learning, and memory (Harris, et al., Trends Neurosc1., 2006, 29 (10), 571-577). In mammals, two appetite hormone receptors have been cloned and characterized. They belong to the superfamily of G protein-coupled receptors (Sakurai T. et al., Cell, 1998, 92, 573-585): the appetite hormone-1 receptor (0X or 0X1R) is selective for OX-A, appetite hormone-2 The receptor (OX2 or OX2R) is capable of binding to OX-A and OX-B. It is believed that the physiological role involved in the appetite hormone is expressed by one or both of the OXI receptor and OX 2 (as two subtypes of the appetite hormone receptor).

Appetite hormone receptors can be found in the brains of warm-blooded animals and have many implications in, for example, depression: anxiety; addiction; compulsive mandatory disorders; affective neurosis; depressive neurosis; anxiety Neurosis; depressive disorder; behavioral disorder; mood disorder; sexual dysfunction; sexual psychological dysfunction; gender disorder; schizophrenia; manic depression; mental disorder; dementia; severe mental retardation and dyskinesia, for example Huntington's disease and pruritus; eating disorders such as anorexia, bulimia, cachexia and obesity; addictive feeding behavior; feeding behavior of madness; cardiovascular disease; diabetes; appetite/taste disorder Vomiting, vomiting, nausea; asthma; cancer; Parkinson's disease; Cushing's syndrome/disease; basophilic adenoma; prolactinoma; hyperprolactinemia; pituitary tumor/adenomas; Thalamic disease; inflammatory bowel disease; gastric dysfunction; gastric ulcer; obesity genital degeneration; pituitary disease; pituitary disease; glandular hypofunction; Hyperthyroidism; hypogonadal hypogonadism; Kalman's syndrome (olfactory loss, olfactory dysfunction); functional or psychogenic amenorrhea; hypophyseal hypofunction; hypothalamic hypothyroidism; hypothalamic-adrenal dysfunction; Hyperprolactinemia; hypoglycemia growth hormone deficiency; sudden growth loss; dwarfism; giant disease; acromegaly; disturbed organisms and circadian rhythm; and diseases such as neurological disorders, neurological Pain associated with pain and restless leg syndrome; heart and lung disease, acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; acute myocardial infarction; ischemic or hemorrhagic Sexual stroke; arachnoid hemorrhage; ulcer; allergic reaction; benign prostatic hypertrophy; chronic renal failure; kidney disease; impaired glucose tolerance; migraine; hyperalgesia; pain; increased sensitivity or exaggeration of pain, such as hyperalgesia, burning and Touch pain; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; I and II; arthritic pain; sports trauma pain; pain associated with infections such as HIV; pain after chemotherapy; pain after stroke; post-surgical pain; neuralgia; vomiting, nausea, vomiting; , for example, irritable bowel syndrome and angina pectoris; migraine; bladder incontinence, such as urge incontinence; tolerance to anesthetics or withdrawal anesthesia; sleep disorders; sleep apnea; narcolepsy; insomnia; deep sleep state; And neurodegenerative disorders, including disease-classifying entities such as inhibition-dementia-tremor palsy-muscle atrophy syndrome; epilepsy; seizure disorders and other diseases associated with dysfunction of the common appetite hormone system.

Certain appetite hormone receptor antagonists are disclosed in the following patents: WO 99/09024, WO 99/58533, WO 00/47576, WO 00/47577, WO 00/47580, WO 01/68609, W001/85693, WO 01/ 96302, WO 2002/044172, WO 2002/051232, WO 2002/051838, WO2002/089800, WO 2002/090355, WO 2003/002559, WO 2003/002561, WO 2003/032991, WO2003/037847, WO 2003/041711, WO 2003/051368, WO 2003/051872, WO 2003/051873, WO2004/004733, WO 2004/026866, WO 2004/033418, WO 2004/041807, WO 2004/041816, WO2004/052876, WO 2004/083218, WO 2004 /085403, WO 2004/096780, WO 2005/060959, WO2005/075458, WO2005/118548, WO 2006/067224, WO 2006/110626, WO 2006/127550, WO2007/019234, WO 2007/025069, WO 2007/061763, WO 2007/116374, WO 2007/122591, WO2007/126934, WO 2007/126935, WO 2008/008517, WO 2008/008518, WO 2008/008551, WO2008/020405, WO 2008//026149, WO 2008/038251.

In addition, WO2008147518 (CN101679366 B) discloses the structure shown by the formula (B-I) and MK6096 on the basis of the above patent: (B-I) (MK6096) The effects on activity, solubility, pharmacokinetics, half-life, etc. need to be improved.

It is an object of the present invention to provide a compound of the formula (I) or a pharmaceutically acceptable salt thereof, (I) wherein A is selected from a 3- to 12-membered cyclic hydrocarbon group or a heterocycloalkyl group or a cyclohetero group which is optionally substituted, and the cycloalkyl or heterocycloalkyl or cycloalkyl group may be monocyclic or bicyclic, In the form of a spiro, cyclo or fused ring, the substituent is selected from the group consisting of F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or hydroxy or amine or unsubstituted C _1-6 alkyl or heteroalkyl or alkylene or heteroalkano, halogenated or hydroxy or amine or unsubstituted C _3-8 cyclo or heterocyclyl or cyclohetero or hetero The cyclohetero, heteroatoms or heteroatoms are each independently selected from C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O)O, C _{1- 6} -alkane or C _{3-8 cycloalkane or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C=O, C =S, S(=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of being chemically stable;

B is selected from C(=O), S(=O) or S(=O) ₂ ;

X is selected from (CH ₂ ) _r1 (U) _r2 (CH ₂ ) _r3 which is optionally substituted, and the substituent is selected from the group consisting of F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or hydroxy or amine or unsubstituted C _1-6 alkyl or heteroalkyl or alkino or heteroalkano, halogenated or hydroxy or amine or unsubstituted C _{3 8} acyclic or heterocyclic or cyclohetero or heterocyclic hetero, heteroatoms or heteroatoms independently selected from C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C (=O) NH, C(=O)O, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} Unsubstituted C=NH, C=O, C=S, S(=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is chemically stable Is arbitrary;

r ₁ , r ₃ are each independently selected from 0, 1 or 2, r _{2 is} selected from 0 or 1, and r ₁ , r ₂ and r ₃ are 0 at the same time, and X is a single bond which only serves as a linking;

D, L are each independently selected from selectively substituted CH ₂ , and the substituent is selected from the group consisting of F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or hydroxy or Amine or unsubstituted C _1-6 alkyl or heteroalkyl or alkino or heteroalkano, halo or hydroxy or amine or unsubstituted C _3-8 cyclo or heterocyclyl Or a cyclohetero or heterocyclic hetero group, a hetero atom or a hetero atom, each independently selected from C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O O, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH , C=O, C=S, S(=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms being arbitrary under the premise of being chemically stable;

T is selected from C or a single bond which acts only as a linkage, and when T is selected from a single bond, R ₂ and R ₃ are absent;

M is selected from C(Y)(R _1a ), wherein Q is selected from C(R _1b )(R _1c ), or M is selected from C(R _1b )(R _1c ), where Q is selected from C(Y) )(R _1a );

Y is selected from -(CH ₂ ) _r4 (G) _r5 (CH ₂ ) _r6 -Y ₁ , and Y _{1 is} selected from the group consisting of -OE or the formula (Y ₂ ). (Y ₂ )

G is selected from halogenated or hydroxy or amine or unsubstituted CH ₂ , C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted NH, O, S, S(=O), S(=O) ₂ , C(=O) or C(=S), the number of substituents being arbitrary under the premise of being chemically stable;

r ₄ , r ₆ are each independently selected from 0, 1 or 2, r _{5 is} selected from 0 or 1, and r ₄ , r ₅ and r ₆ are 0 at the same time, the corresponding structure is a single bond which only serves as a linking;

E is selected from a 5 to 6 membered cycloalkyl or heterocyclic group which is optionally substituted, and the substituent is selected from the group consisting of F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or Hydroxy or amine or unsubstituted C _1-6 alkyl or heteroalkyl or alkylene or heteroalkano, halogenated or hydroxy or amine or unsubstituted C _3-8 ring or Heterocyclyl or cyclohetero or heterocyclohetero, heteroatoms or heteroatoms, each independently selected from _C1-6 alkane or _{C3-8 cycloalkane or} unsubstituted C(=O)NH, C (=O)O, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C=O, C=S, S(=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of being chemically stable;

Y _2a , Y _2b , Y _2c , Y _2d , Y _2e , Y _2f , Y _{2g are} selected from selectively substituted CH ₂ , CH, NH, or selected from N, O, S, S(=O), S(=O) ₂ , C(=O) or C(=S), and at least one of Y _2a , Y _2b , Y _2c , Y _2d , Y _2e , Y _2f , Y _2g is selectively substituted CH, CH ₂ or NH, the substituent is selected from F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or hydroxy or amine or unsubstituted C _{1- a 6} alkyl or heteroalkyl or alkynylene or heteroalkanyl, halo or hydroxy or an amine or unsubstituted C _3-8 cyclo or heterocyclyl or cyclohetero or heterocyclo, The heteroatoms or heteroatoms are each independently selected from C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O)O, C _1-6 alkane or C _{3-8 cycloalkyl or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C=O, C=S, S (=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of being chemically stable;

Represents a single or double button;

R _1a , R _1b , R _1c , R ₂ , R ₃ are each independently selected from H, F, Cl, Br, I, CN, =0, =S, OH, SH, NH ₂ , halo or hydroxy or Amine or unsubstituted C _1-6 alkyl or heteroalkyl or alkino or heteroalkano, halo or hydroxy or amine or unsubstituted C _3-8 cyclo or heterocyclyl Or a cyclohetero or heterocyclic hetero group, a hetero atom or a hetero atom, each independently selected from C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O O, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH , C=O, C=S, S(=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of being chemically stable, or R ₂ , R _{3 is} selectively joined to form a ring;

The compound or a pharmaceutically acceptable salt thereof comprises one or more palmitic centers.

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein A is selected from the structural unit represented by the formula (A ₁ ) or (A ₂ ): (A ₁ ) (A ₂ )

Wherein Z ₁ , Z ₂ , Z ₃ , Z ₄ , Z ₅ are each independently selected from halo or hydroxy or amine or unsubstituted CH or CH ₂ , or C _1-6 alkane or C _{3 - 8-cycloalkane or} unsubstituted C(=O)NH or NH, C=N, N, O, S, S(=O), S(=O) ₂ , C(=O)O, C( =O) or C(=S), the number of substituents being arbitrary under the premise of being chemically stable;

V ₁ , V ₂ , V ₃ , V ₄ , V ₅ are each independently selected from halo or hydroxy or amine or unsubstituted CH or CH ₂ , C _1-6 alkane or C _{3-8 naphthenic Generation or} unsubstituted C(=O)NH or NH, C=N, C, N, O, S, S(=O), S(=O) ₂ , C(=O)O, C(= O) or C (= S), and at least one of V _1-5 is C or N, and the number of substituents is arbitrary under the premise of being chemically stable;

Represents a single or double button;

R ₄ and R ₆ are each independently selected from H, F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or hydroxy or amine or unsubstituted C _{1 -6} alkyl or heteroalkyl or alkylene or heteroalkano, halogenated or hydroxy or amine or unsubstituted C _3-8 cyclic or heterocyclic or cyclohetero or heterocyclic hetero , heteroatoms or heteroatoms are independently selected from C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O)O, C _1-6 alkyne Or C _{3-8 cycloalkyl or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C=O, C=S, S(=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of being chemically stable;

R ₅ and R ₇ are each independently selected from a 5 to 6 membered cycloalkyl or heterocyclic group which is optionally substituted, and the substituent is selected from the group consisting of F, Cl, Br, I, CN, =O, =S, OH, SH. , NH ₂ , halogenated or hydroxy or amine or unsubstituted C _1-6 alkyl or heteroalkyl or alkino or heteroalkano, halogenated or hydroxy or amine or unsubstituted a C _3-8 cyclo or heterocyclic group or a cyclohetero or heterocyclic hetero group, each independently selected from a C _1-6 alkane or a C _{3-8 cycloalkane or} an unsubstituted C (=O) NH, C(=O)O, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted NH, O, S, C _1-6 alkane or C _{3-8 ring Alky or} unsubstituted C=NH, C=O, C=S, S(=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is chemically stable Under the premise of arbitrary;

n _{4 is} selected from 0, _1, 2, 3, 4; and

n _{6 is} selected from 0, 1, 2, and 3.

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein the structural unit Selected from phenyl or pyridyl, It is selected from a furyl group, a thienyl group or a thiazolyl group.

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein the formula (A ₂ ) is selected from the structure represented by the formula (A ₂₁ ): (A ₂₁ )

In the formula, V ₁ , V ₂ , V ₃ , V ₄ , V ₅ , R ₆ , R ₇ , and n ₆ are as defined in the formula (A ₂ ).

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein A is selected from the structural unit represented by the formula ( _A22 ): (A ₂₂ )

Wherein R ₆ and R ₇ are as defined in the formula (A ₂ ); and n _{6a is} selected from 0, 1 or 2.

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein the 5 to 6 membered cycloalkyl or heterocyclic group in the R ₅ and R ₇ are each independently selected from a phenyl group, a pyridyl group, a furyl group, a thienyl group, Thiazolyl, pyrimidinyl, pyrazolyl, 1,2,3-triazolyl or 1,2,5-triazolyl.

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein said A is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , .

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein the formula (Y ₂ ) is selected from the structure represented by the formula (Y ₂₁ ): (Y ₂₁ )

In the formula, Y _2a , Y _2b , Y _2c , Y _2d , Y _2e , Y _2f , Y _2g are as defined in the formula (I).

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein the formula (Y ₂₁ ) is selected from the structures represented by the formula (Y ₂₂ ) which are optionally substituted: (Y ₂₂ )

Wherein the substituent is selected from the group consisting of F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or hydroxy or amine or unsubstituted C _1-6 alkyl or hetero Alkyl or alkynyl or heteroalkanyl, halo or hydroxy or amine or unsubstituted C _3-8 cyclo or heterocyclyl or cyclohetero or heterocyclo, heteroatom or heteroatom Individually selected from C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O)O, C _1-6 alkane or C _{3-8 ring Alky or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C=O, C=S, S(=O) and / or S (= O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of being chemically stable.

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein Y is selected from the group consisting of selectively substituted or .

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein Y is selected from -CH ₂ -OE or -OE, wherein E is as defined in formula (I).

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein E is selected from the structural unit represented by the formula (E _a ): (E _a )

Wherein E ₁ , E ₂ , E ₃ , and E ₄ are each independently selected from halo or hydroxy or amine or unsubstituted CH, N;

R ₈ and R ₉ are each independently selected from H, F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or hydroxy or amine or unsubstituted C _{1 -6} alkyl or heteroalkyl or alkylene or heteroalkano, halogenated or hydroxy or amine or unsubstituted C _3-8 cyclic or heterocyclic or cyclohetero or heterocyclic hetero , heteroatoms or heteroatoms are independently selected from C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O)O, C _1-6 alkyne Or C _{3-8 cycloalkyl or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C=O, C=S, S(=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of being chemically stable.

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein the structural unit It is defined as a phenyl or pyridyl group, or it is replaced with a thienyl or furyl group.

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein Y is selected from the group consisting of: .

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein U, X, and G are each independently selected from NH or N(C _1-6 alkyl).

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein R _1a , R _1b , R _1c are each independently selected from H, methyl or fluorine.

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein R ₂ and R ₃ are each independently selected from H, methyl, fluoro or cyclopropyl.

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein R ₂ and R _{3 are} bonded to a 3- to 8-membered cycloalkyl group.

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein R ₂ and R _{3 are} bonded to a cyclopropyl group.

Preferably, the above compound or a pharmaceutically acceptable salt thereof, wherein the C _1-6 alkyl group is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, wherein the propyl, butyl, pentyl The hexyl group or the hexyl group is selectively cyclized or partially cyclized.

Preferably, the above compound or a pharmaceutically acceptable salt thereof has the following structure: , , , , , , , , , , , , , , , , , , .

Another object of the present invention is to provide a pharmaceutical composition comprising a therapeutically effective amount of the above compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Another object of the present invention is to provide a therapeutic compound for the treatment of insomnia, chronic obstructive pulmonary disease, obstructive sleep apnea, lethargy, anxiety, obsessive-compulsiveness, panic disorder, nicotine dependence, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. Use in medications for eating disorders.

The term "pharmaceutically acceptable salt" refers to a salt of a compound of the invention prepared from a compound having a particular substituent found in the present invention and a relatively non-toxic acid or base. When a relatively acidic functional group is contained in the compound of the present invention, a base addition salt can be obtained by contacting a neutral amount of such a compound with a sufficient amount of a base in a neat solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic ammonia or magnesium salts or similar salts. When a relatively basic functional group is contained in the compound of the present invention, an acid addition salt can be obtained by contacting a neutral form of such a compound with a sufficient amount of an acid in a neat solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, hydrogencarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, Hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and an organic acid salt, such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, Similar acids such as fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and methanesulfonic acid; and salts of amino acids (such as arginine, etc.) And salts of organic acids such as glucuronic acid (see Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science 66: 1-19 (1977)). Certain specific compounds of the invention contain both basic and acidic functional groups which can be converted to any base or acid addition salt.

Preferably, the salt is contacted with a base or acid in a conventional manner, and the parent compound is separated, thereby regenerating the neutral form of the compound. The parent form of the compound differs from the form of its various salts by certain physical properties, such as differences in solubility in polar solvents.

As used herein, a "pharmaceutically acceptable salt" is a derivative of a compound of the invention wherein the parent compound is modified by addition to an acid or to a base. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of bases such as amines, alkali metal or organic salts of acid groups such as carboxylic acids, and the like. Pharmaceutically acceptable salts include the conventional non-toxic salts or quaternary ammonium salts of the parent compound, for example salts formed from non-toxic inorganic or organic acids. Conventional non-toxic salts include, but are not limited to, those derived from inorganic acids and organic acids selected from the group consisting of 2-ethyloxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid. , benzenesulfonic acid, benzoic acid, hydrogencarbonate, carbonic acid, citric acid, edetic acid, ethane disulfonic acid, ethanesulfonic acid, fumaric acid, glucoheptose, gluconic acid, glutamic acid, glycolic acid , hydrobromic acid, hydrochloric acid, hydroiodide, hydroxyl, hydroxynaphthalene, isethionethane, lactic acid, lactose, dodecyl sulfonic acid, maleic acid, malic acid, mandelic acid, methane sulfonic acid, nitric acid, oxalic acid , pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturaldehyde, propionic acid, salicylic acid, stearic acid, acetic acid, succinic acid, sulfamic acid, p-aminobenzenesulfonic acid, sulfuric acid, tannin , tartaric acid and p-toluenesulfonic acid.

The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound containing an acid group or a base by conventional chemical methods. In general, such salts are prepared by reacting these compounds in water or an organic solvent or a mixture of the two via a free acid or base form with a stoichiometric amount of a suitable base or acid. Generally, a nonaqueous medium such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile is preferred.

In addition to the form of the salt, the compounds provided herein also exist in the form of prodrugs. Prodrugs of the compounds described herein are readily chemically altered under physiological conditions to convert to the compounds of the invention. In addition, prodrugs can be converted to the compounds of the invention by chemical or biochemical methods in an in vivo setting.

Certain compounds of the invention may exist in unsolvated or solvated forms, including hydrated forms. In general, the solvated forms are equivalent to the unsolvated forms and are included within the scope of the invention. Certain compounds of the invention may exist in polycrystalline or amorphous form.

Certain compounds of the invention may have asymmetric carbon atoms (optical centers) or double bonds. Racemates, diastereomers, geometric isomers and individual isomers are included within the scope of the invention.

Unless otherwise specified, the term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, including variants of heavy hydrogen and hydrogen, as long as the valence of the particular atom is normal and after substitution The compound is stable. When the substituent is a keto group (i.e., =0), it means that two hydrogen atoms are substituted. Ketone substitution does not occur on the aryl group. The term "selectively substituted" means that it may or may not be substituted, and unless otherwise specified, the kind and number of substituents may be arbitrary on the basis of chemically achievable.

Unless otherwise specified, when any variable (e.g., R) occurs more than once in the composition or structure of the compound, its definition in each case is independent. Thus, for example, if a group is substituted by 0-2 R, the group can be selectively substituted at most by two Rs, and R in each case has an independent option. Furthermore, combinations of substituents and/or variants thereof are permissible only if such combinations result in stable compounds.

When one of the variables is selected from a single bond, it means that the two groups to which they are attached are directly linked. For example, when L represents a single bond in A-L-Z, the structure is actually A-Z.

Unless otherwise specified, when a group or a bond of a substituent may be cross-linked to two atoms on a ring, such a group or substituent may be bonded to any atom on the ring. When the recited group or substituent does not indicate which atom is attached to a compound included in the chemical structural formula, but not specifically mentioned, such a group or substituent may be bonded through any of its atoms. Combinations of groups or substituents and/or variants thereof are permissible only if such combinations result in stable compounds. For example, structural unit or It is indicated that it can be substituted at any position on the cyclohexyl or cyclohexadiene. Unless otherwise specified, the term "hydrocarbyl" or its subordinate concept (such as alkyl, alkenyl, alkynyl, phenyl, etc.) by itself or as part of another substituent means straight-chain, branched or cyclic The hydrocarbon radical or a combination thereof may be fully saturated, unitary or polyunsaturated, may be monosubstituted, disubstituted or polysubstituted, and may include divalent or polyvalent radicals having a specified number of carbon atoms (eg, C1 ₎ -C ₁₀ represents 1 to 10 carbons). The hydrocarbon group includes an aliphatic hydrocarbon group including an chain hydrocarbon group and a cyclic hydrocarbon group, and includes, but not limited to, an alkyl group, an alkenyl group, and an alkynyl group, and the aromatic hydrocarbon group includes, but not limited to, an aromatic hydrocarbon group of 6 to 12 members. For example, benzene, naphthalene, and the like. In some embodiments, the term "alkyl" refers to a straight or branched or cyclic group of atoms or a combination thereof, which may be fully saturated, unitary or polyunsaturated, and may include divalent and multivalent radicals. Examples of saturated hydrocarbon radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, isobutyl, cyclohexyl, (cyclohexyl). A homolog or isomer of a methyl group, a cyclopropylmethyl group, and an atomic group such as n-pentyl, n-hexyl, n-heptyl, n-octyl. The unsaturated alkyl group has one or more double or triple bonds, and examples thereof include, but are not limited to, a vinyl group, a 2-propenyl group, a butenyl group, a crotyl group, a 2-isopentenyl group, and a 2-(butadienyl group). ), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and higher homologs and Structure.

Unless otherwise specified, the heteroalkyl, heterocyclyl, hydrocarbyl, cyclohetero, heteroalkylhetero, heterocyclylhetero group means a hetero atom or a hetero atom group, a hetero atom or a hetero atom group on a specific group. Including but not limited to N, NH, substituted or protected NH, O, S, S (= O), S (= O) ₂ , the so-called heterohydrocarbyl, heterocyclic group is connected to the rest of the molecule through carbon atoms , that is, a hetero atom may be located at any internal position of the group (except that the group is attached to the rest of the molecule); the so-called hydrocarbon heterocycle, cyclohetero is attached to the rest of the molecule through a hetero atom, ie, The atom is located at a position where the group is attached to the rest of the molecule; the so-called heteroalkylhetero, heterocyclyl is attached to the remainder of the molecule through a heteroatom, wherein the heteroatom can be located at any internal position of the group (including This group is attached to the rest of the molecule).

Unless otherwise specified, the term "heterohydrocarbyl" or its subordinate concept (such as heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, etc.), by itself or in combination with another term, means a stable straight chain, branched chain. Or a cyclic hydrocarbon radical or a combination thereof having a number of carbon atoms and at least one heteroatom. In some embodiments, the term "heterohydrocarbyl" or its subordinate concept (such as heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, and the like), by itself or in combination with another term, means a stable straight chain. A hydrocarbon group of a chain or a combination thereof having a number of carbon atoms and at least one hetero atom. In a typical embodiment, the heteroatoms are selected from the group consisting of B, O, N, and S, wherein the nitrogen and sulfur atoms are selectively oxidized and the nitrogen heteroatoms are selectively quaternized. The heteroatoms B, O, N and S may be located at any internal position of the heterohydrocarbyl group (except where the hydrocarbyl group is attached to the rest of the molecule). Examples include, but are not limited to, -CH ₂ -CH ₂ -O-CH ₃ , -CH ₂ -CH ₂ -NH-CH ₃ , -CH ₂ -CH ₂ -N(CH ₃ )-CH ₃ , -CH ₂ -S -CH ₂ -CH ₃ , -CH ₂ -CH ₂ , -S(O)-CH ₃ , -CH ₂ -CH ₂ -S(O) ₂ -CH ₃ , -CH=CH-O-CH ₃ , - CH ₂ -CH=N-OCH ₃ and -CH=CH-N(CH ₃ )-CH ₃ . Up to two heteroatoms may be consecutive, for example, -CH ₂ -NH-OCH _3.

Unless otherwise specified, the terms "alkoxy", "alkylamino" and "alkylthio" (or thioalkoxy) are customary and are meant to be attached to the molecule through an oxygen, amino or sulfur atom, respectively. The rest of those alkyl groups.

Unless otherwise specified, the terms "cycloalkyl", "heterocycloalkyl", "cyclohetero" or subordinates thereof (such as aryl, heteroaryl, aryl, cycloalkyl, heterocycloalkyl, ring) Alkyl, cycloalkenyl, heterocycloalkenyl, cycloalkenyl, cycloalkynyl, heterocycloalkynyl, cycloalkynyl, and the like, by themselves or in combination with other terms, respectively denote a cyclized "hydrocarbyl group", Heterohydrocarbyl" or "hydrocarbyl". Examples of cycloalkyl groups include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Non-limiting examples of heterocyclic groups include 1-(1,2,5,6-tetrahydropyridyl), 1-acridinyl, 2-acridinyl, 3-acridinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothiophen-2-yl, tetrahydrothiophen-3-yl, 1-pyridazinyl and 2-pyridazinyl.

Unless otherwise specified, the term "halo" or "halogen", by itself or as part of another substituent, denotes a fluorine, chlorine, bromine or iodine atom. Further, the term "haloalkyl" is intended to include both monohaloalkyl and polyhaloalkyl. For example, the term "halo(C ₁ -C ₄ )alkyl" is intended to include, but is not limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like. Wait.

Unless otherwise specified, the term "aryl" denotes a polyunsaturated, aromatic hydrocarbon substituent which may be monosubstituted, disubstituted or polysubstituted, which may be monocyclic or polycyclic (preferably 1 to 3 rings), They are fused together or covalently linked. The term "heteroaryl" refers to an aryl (or ring) containing one to four heteroatoms. In an illustrative example, the heteroatoms are selected from the group consisting of B, N, O, and S, wherein the nitrogen and sulfur atoms are selectively oxidized and the nitrogen atom is selectively quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of aryl or heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyridyl Azyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxan Azyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thiophene , 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-benzothiazolyl, indolyl, 2-benzimidazolyl, 5-indenyl, 1-isoquinolyl, 5-isoquinolinyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl and 6-quinolinyl. The substituents of any of the above aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.

Unless otherwise specified, for ease of use, aryl groups, when used in conjunction with other terms (eg, aryloxy, arylthio, aralkyl), include aryl and heteroaryl rings as defined above. Thus, the term "aralkyl" is intended to include those radicals to which an aryl group is attached to an alkyl group (eg, benzyl, phenethyl, pyridylmethyl, and the like), including wherein the carbon atom (eg, methylene) has been, for example, oxygen. Those alkyl groups substituted by an atom, such as phenoxymethyl, 2-pyridyloxymethyl 3-(1-naphthyloxy)propyl and the like.

Unless otherwise specified, "ring" means substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted hetero Aryl. The so-called ring includes a fused ring. The number of atoms on the ring is usually defined as the number of members of the ring. For example, "5 to 7 membered rings" means that 5 to 7 atoms are arranged in a circle. Unless otherwise specified, the ring optionally contains from 1 to 3 heteroatoms. Therefore, the "5-7 membered ring" includes, for example, a phenyl group, a pyridyl group and an acridinyl group; on the other hand, the term "5-7 membered heterocycloalkyl ring" includes a pyridyl group and an acridinyl group, but does not include a phenyl group. . The term "ring" also includes ring systems containing at least one ring, each of which "ring" independently conforms to the above definition.

The term "heteroatom" as used herein, unless otherwise specified, includes atoms other than carbon (C) and hydrogen (H), including, for example, oxygen (O), nitrogen (N), sulfur (S), cerium (Si), cerium ( Ge), aluminum (Al) and boron (B).

Unless otherwise specified, the term "leaving group" refers to a functional group or atom that can be substituted by another functional group or atom by a substitution reaction (eg, an affinity substitution reaction). For example, representative leaving groups include triflate; chlorine, bromine, iodine; sulfonate groups such as mesylate, tosylate, p-bromobenzenesulfonate, p-toluenesulfonic acid Ester and the like; an oxime group such as an ethoxy group, a trifluoroacetoxy group or the like.

Unless otherwise specified, the term "protecting group" includes, but is not limited to, "amino protecting group", "hydroxy protecting group" or "thiol protecting group." The term "amino protecting group" refers to a protecting group suitable for preventing side reactions at the amino nitrogen position. Representative amino protecting groups include, but are not limited to, indolyl; indenyl, such as alkanealkyl (e.g., ethyl, trichloroethyl or trifluoroethyl); alkoxycarbonyl, such as tert-butyl Oxycarbonyl (Boc); arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr) 1,1-di-(4'-methoxyphenyl)methyl; formylalkyl, such as trimethylcarbinyl (TMS) and tert-butyldimethylformamidin (TBS), and the like. The term "hydroxy protecting group" refers to a protecting group suitable for use in preventing hydroxy side reactions. Representative hydroxy protecting groups include, but are not limited to, alkyl groups such as methyl, ethyl and t-butyl groups; fluorenyl groups such as alkane fluorenyl groups (e.g., ethenyl); arylmethyl groups such as benzyl (Bn) , p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (diphenylmethyl, DPM); germyl, such as trimethylmethanyl (TMS) and Tert-butyldimethylformamidinyl (TBS) and the like.

Unless otherwise specified, examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl. "Alkoxy" represents the above alkyl group having a specified number of carbon atoms attached through an oxygen bridge. The C _1-6 alkoxy group includes a C ₁ , C ₂ , C ₃ , C ₄ , C ₅ and C ₆ alkoxy groups. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy and S- Pentyloxy. "Cycloalkyl" includes saturated cyclic groups such as cyclopropyl, cyclobutyl or cyclopentyl. The 3-7 cycloalkyl group includes C ₃ , C ₄ , C ₅ , C ₆ and C ₇ cycloalkyl groups. "Alkenyl" includes hydrocarbon chains in a straight or branched configuration wherein one or more carbon-carbon double bonds, such as vinyl and propylene groups, are present at any stable site on the chain.

Unless otherwise specified, the term "halo" or "halogen" refers to fluoro, chloro, bromo and iodo.

Unless otherwise specified, the term "heterocycle" or "heterocyclyl" means a stable monocyclic or bicyclic heterocycle which may be saturated, partially unsaturated or unsaturated (aromatic) which comprise carbon The atom and 1, 2, 3 or 4 ring heteroatoms independently selected from N, O and S, wherein any of the above heterocyclic rings may be fused to a phenyl ring to form a bicyclic ring.

Unless otherwise specified, examples of heterocyclic compounds include, but are not limited to, acridinyl, anthracycline, benzimidazolyl, benzofuranyl, benzofuranylfuranyl, benzindenylphenyl, benzoxazole , benzoxazolinyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, carbazolyl, 4aH - carbazolyl, porphyrinyl, benzopyranyl, chromenyl, porphyrinyldecahydroquinolinyl, 2H, 6H-1, 5,2-dithiazinyl, dihydrofuran[ 2,3-b]tetrahydrofuranyl, furyl, furfuryl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-carbazolyl, nonenyl, indanyl, mesoindol, hydrazine Sulfhydryl, 3H-fluorenyl, isatino, isobenzofuranyl, pyranyl, isodecyl, isoindoline, isoquinolyl, isothiazolyl, isoxazolyl, methylene Dioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1, 2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, isoxazolyl, hydroxy Indenyl, phenanthryl, phenanthroline, phenazinyl, phenothiazine, benzoxanthyl, phenolzinyl, pyridazinyl, pyridazinyl, acridinyl, acridinone, 4 - acridone, piperonyl, pteridinyl, fluorenyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridylthiazole , pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinazinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl , tetrahydroisoquinolyl, tetrahydroquinolyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadi Azyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thioxyl, thiazolyl, isothiazolylthiophenyl, thienyl, thienooxazolyl, thienothiazole Base, thienoimidazolyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl And 呫 tons base. Also included are fused ring and spiro compounds. Unless otherwise specified, the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, combinations thereof with other chemical synthesis methods, and techniques in the art. Equivalent alternatives well known to those skilled in the art, including, but not limited to, embodiments of the invention.

Unless otherwise specified, the structure of the compound is determined by nuclear magnetic resonance (NMR) or/and liquid phase mass spectrometry (LCMS). The NMR shift (d) is given in units of 10 ^-6 (ppm). The NMR was measured by a Bruker AVANCE-400 nuclear magnetic apparatus, and the solvent was deuterated dimethyl hydrazine (DMSO- d ₆ ), deuterated chloroform (CDCl ₃ ), deuterated methanol (CD ₃ OD), and the internal standard was four. Methyl decane (TMS).

Unless otherwise specified, the absolute configuration is determined by conventional methods of single crystal X-ray diffraction. The absolute configuration of compound 1-16 is used as an example. The instrument used is a Bruker APEX-II CCD with a temperature of 296K. The radiation wavelength was 1.54178 and the radiation type was Cu-Ka. The test results are shown in Figure 1.

Unless otherwise specified, liquid phase mass spectrometry LCMS was measured using agilent 1200 (Xtimate C18 2.1*30 mm column) and mass spectrometry section using Agilent 6110 (ion source: ESI).

Unless otherwise specified, HPLC measurements were performed using a Shimadzu LC10AD high pressure liquid chromatograph (Xtimate C18 2.1*30 mm column).

Unless otherwise specified, thin-layer chromatography tantalum sheets use Yantai Huanghai HSGF254 or Qingdao GF254 tannin sheets, and thin-layer chromatography (TLC) uses a size of 0.15 mm to 0.2 mm for thin-layer chromatography. The specifications are from 0.4 mm to 0.5 mm.

Unless otherwise specified, column chromatography generally uses Yantai Huanghai silicone 200-300 mesh silicone as the carrier.

Unless otherwise specified, the known starting materials of the present invention may be synthesized by or according to methods known in the art, or may be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, TCI, Alfa, 韶Accela ChemBio Inc., Beijing Coupling and other companies.

Unless otherwise specified, the examples can be carried out under an argon atmosphere or a nitrogen atmosphere unless otherwise specified in the examples. An argon atmosphere or a nitrogen atmosphere means that the reaction flask is connected to an argon or nitrogen balloon having a volume of about 1 L.

Unless otherwise specified, a hydrogen atmosphere means that the reaction flask is connected to a hydrogen balloon having a volume of about 1 liter.

Unless otherwise specified, the pressurized hydrogenation reaction uses a Parr 3916EKX type hydrogenation apparatus and a clear blue QL-500 type hydrogen generator or a HC2-SS type hydrogenation apparatus. The hydrogenation reaction is usually evacuated, charged with hydrogen, and operated three times.

Unless otherwise specified, the microwave reaction used a CEM Discover-S Model 908860 or Biotage Initiator 60 microwave reactor.

Unless otherwise specified, unless otherwise stated in the examples, the solution means an aqueous solution.

Unless otherwise specified, the examples are not specifically described, and the reaction temperature is room temperature and is 20 ° C to 30 ° C.

Unless otherwise specified, the progress of the reaction in the examples was monitored by thin layer chromatography (TLC). The system used for the reaction was: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system. , C: petroleum ether and ethyl acetate system, D: acetone, the volume ratio of the solvent is adjusted according to the polarity of the compound.

Unless otherwise specified, the column chromatography eluent system and the thin layer chromatography developer system used for the purification of the compound include: A: dichloromethane and methanol systems, B: petroleum ether and ethyl acetate systems, C: In the dichloromethane and acetone systems, the volume ratio of the solvent is adjusted depending on the polarity of the compound, and may be adjusted by adding a small amount of an alkaline or acidic reagent such as triethylamine or acetic acid.

Unless otherwise specified, the instrument used for HPLC separation was Shimadzu LC-8A Prep.; the separation column model was Phenomenex Luna C18 250*50 mm, 10 μm; the fluidity was: A: water (0.2 % FA), B: CH ₃ CN The mobile phase gradient was determined according to the polarity of the sample: 0~100% B; the separation time was 25 min; the flow rate was 90 mL/min; and the detection wavelength was 220/254 nm.

The invention is specifically described by the following examples, which are not intended to limit the invention.

All solvents used in the present invention are commercially available and can be used without further purification unless otherwise specified.

Unless otherwise specified, the invention employs the following abbreviations: aq for water; HATU for O-7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethylurea Hexafluorophosphate; EDC stands for N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride; m-CPBA stands for 3-chloroperoxybenzoic acid; eq stands for equivalent, etc. CDI stands for carbonyl diimidazole; DCM stands for dichloromethane; PE stands for petroleum ether; DIAD stands for diisopropyl azodicarboxylate; DMF stands for N,N-dimethylformamide; DMSO stands for dimethyl hydrazine EtOAc stands for ethyl acetate; EtOH stands for ethanol; MeOH stands for methanol; CBz stands for benzyloxycarbonyl, an amine protecting group; BOC stands for t-butylcarbonyl is an amine protecting group; HOAc stands for acetic acid; NaCNBH ₃ stands for cyano Sodium borohydride; rt stands for room temperature; O/N stands for overnight; THF stands for tetrahydrofuran; Boc ₂ O stands for di-tert-butyldicarbonate; TFA stands for trifluoroacetic acid; DIPEA stands for diisopropylethylamine; SOCl ₂ Represents thallium chloride; CS ₂ stands for carbon disulfide; TsOH stands for p-toluenesulfonic acid; NFSI stands for N-fluoro-N-(phenylsulfonyl)benzenesulfonamide; NCS stands for 1-chloropyrrolidine-2,5-di Ketone; nB u ₄ NF represents tetrabutylammonium fluoride; iPrOH represents 2-propanol; mp represents a melting point.

Unless otherwise specified, the compounds are named by hand or by ChemDraw® software, and the commercially available compounds are given the supplier's catalogue name.

Compared with the prior art, the compound of the present invention is highly efficient, low in toxicity, and has achieved remarkable and unexpected progress in activity, half-life, solubility and pharmacokinetics, and is more suitable for pharmaceuticals.

The invention is described in detail below by the examples, but is not intended to limit the invention. The present invention has been described in detail herein, and the specific embodiments thereof are disclosed, and various changes and modifications may be made to the embodiments of the present invention without departing from the spirit and scope of the invention. It is obvious. Examples 1, 2 A wavy key indicates that the key may be facing up or down and is not affected by other groups (the same below). The first step (synthesis of 1-3)

Compound 1-1 (10.0 g, 44.4 mmol) was dissolved in 55 mL of tetrahydrofuran at -78 ^o C, was slowly added dropwise LDA (24.4 mL, 0.0488 mol) , at -78 ^o C, stirred for 1 hour. Maintaining the temperature at -78 ^o C, the reaction was added dropwise Compound 1-2, after completion of the addition, the temperature was slowly elevated to room temperature, the reaction was stirred at room temperature overnight. The reaction mixture was poured into aq. 50 mL of a saturated aqueous solution of sodium chloride was added thereto, and extracted with ethyl acetate (100 mL × 3). The organic phase was combined and washed with water (100 mL×2) and saturated sodium chloride solution (100 mL×2). Drying over anhydrous sodium sulfate, filtration and purification by column chromatography (EtOAc:EtOAc:EtOAc) (The solid precipitated after cooling.) LC/MS: 198.0 (M-Boc+H ⁺ ). Step 2 (Synthesis of 1-4)

Compound 1-3 (1.5 g, 5.05 mmol) was dissolved in 15 mL methanol and NaBH ₄ (192 mg, 5.05 mmol). The reaction was stirred at room temperature for 12 hours. The reaction mixture was quenched by the addition of 20 mL of water. The mixture was concentrated and extracted with ethyl acetate (20 mL×3). The organic phase was combined with water (100 mL×2) and saturated sodium chloride solution (100 mL×2) After washing, it was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to afford product 1-4. The third step (synthesis of 1-5)

The crude compound 1-4 (1.4 g) was dissolved in 40 mL of dichloromethane, and then, at 0 ^o C, triethylamine (1.01 g, 10 mmol) and methanesulfonium chloride (1.12 g, 9.86 mmol) were added and stirred. After 30 minutes, it was allowed to warm to room temperature and stirred at room temperature for 10 hours. The reaction mixture was poured into water and extracted with dichloromethane (100 mL×3). The organic phase was combined, washed sequentially with water (100 mL×2), saturated sodium chloride solution (100 mL×2) and dried over anhydrous sodium sulfate. Filtration and concentration of the filtrate under reduced pressure afforded product 1-5. The fourth step (synthesis of 1-6)

The crude compound 1-5 (about 600 mg) was dissolved in 10 mL DMF was added DBU (4 g, 16 mmol) , was heated to 100 ^o C for 16 hours. The reaction solution was cooled to room temperature, and then added with 50 mL of water and ethyl acetate (20 mL×2), and the organic phase was combined and washed with water (20 mL×2) and saturated sodium chloride solution (20 mL×2). The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated evaporated. Total step yield: 30%). LC/MS: 182.0 (M-Boc+H+), 226.0 (M-56+H+), 304.0 (M+Na+) ¹ H NMR (400 MHz, CDCl3) δ 6.75 (s, 1H), 4.34~4.32 (m , 1H), 4.10~4.02 (m, 2H), 2.96~2.90 (m, 1H), 2.08~2.02 (m, 2H), 1.97~1.91 (m, 2H), 1.63~1.55 (m, 2H), 1.45 (s, 9H), 1.42~1.28 (m, 3H). The fifth step (synthesis of 1-7)

Compound 1-6 (300 mg, 1.06 mmol) was dissolved in 20 mL of ethanol, and then wet Pd/C (50 mg, 5%) was added and stirred overnight under a hydrogen atmosphere. The reaction mixture was filtered, and the filtrate was evaporated to ethylamine. The sixth step (synthesis of 1-8)

Compound 1-7 (300 mg, 1.06 mmol) was dissolved in 30 mL of tetrahydrofuran at 0 ^o C, was added in small portions LAH (80 mg, 2 mmol) , the ice bath was removed after addition was slowly raised to The reaction was carried out at room temperature for 4 hours at room temperature. The reaction liquid was sequentially added with 0.08 mL of water, 0.08 mL of a 15% aqueous solution of sodium hydroxide and 0.24 mL of water, and a small amount of magnesium sulfate was added thereto, stirred for 10 minutes, filtered, and the filtrate was spun to give the product 1-8. The product was directly purified without purification. The next step is to react. LC/MS: 237.0 (M-Boc+H ⁺ ), 337.1 (M+H ⁺ ) Step 7 (Synthesis of 1-10)

Compound 1-8 (280mg, 1.16 mmol) was dissolved in 14 mL of DMF at 0 ^o C, was added in small portions NaH (139 mg, 3.48 mmol) , keeping the temperature constant, stirred for 30 minutes, slowly Compound 1-9 was added dropwise slowly, and the mixture was allowed to warm to room temperature, and reacted at room temperature for 10 hours. The reaction solution was poured into 30 mL of water, and 10 mL of a saturated aqueous solution of sodium chloride was added thereto, with ethyl acetate (10 mL× 3) Extraction, the organic phase is combined, washed with water (10 mL × 2), saturated sodium chloride solution (10 mL × 2), dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product. Ether: ethyl acetate = 50:1) gave 1-10 (150 mg,yield: 42%). The eighth step (synthesis of 1-11)

Compound 1-10 (300 mg) was isolated by preparative HPLC to give the racemic product 1-11 (120 mg, 80%). The ninth step (synthesis of 1-13)

Compound 1-11 (120 mg) was dissolved in 4 mL of ethyl acetate. EtOAc (4 mL, 4M). In the acid salt form, the product was directly subjected to the next reaction without purification. The tenth step (synthesis of 1-15)

Compound 1-13 (120 mg, 0.32 mmol), compound 1-14 (77 mg, 0.38 mmol), HATU (182 mg, 0.48 mmol) and DIEA (124 mg, 0.96 mmol) were dissolved in 5 mL of DMF. After stirring for 3 hours under temperature, the reaction solution was poured into a brine solution and extracted with ethyl acetate (10 mL×3). The organic phase was combined and washed with water (10 mL×2) and saturated sodium chloride solution (10 mL×2) , spin dry to give product 1-15 (28 mg, white solid, yield: 16%). ¹ H NMR (400 MHz, MeOD) δ 8.01 (s, 1H), 7.93~7.88 (m, 2H), 7.75~7.73 (m, 1H), 7.52~7.45 (m, 2H), 7.41~7.36 (m, 1H), 6.86 (s, br, 0.5H), 6.41~6.38 (m, 0.5H), 4.75~4.66(m, 1H), 4.48~4.33(m, 1H), 4.14~4.04(m, 1H), 3.77~3.72(m, 1H), 2.45~2.42(m, 1H), 2.30~225(m, 1H), 1.94(s, 3H), 1.87~1.83(m, 4H), 1.67~1.46(m, 3H ). The eleventh step (synthesis of 1-16 and 2-1)

The compound racemic product 1-15 (28 mg) was separated via SFC (isolation method: instrument model: MG II preparative SFC; separation column: phenomenex Lux C2, 250 x 30 mm I.D.; mobile phase: A: CO ₂ , B: ethanol (0.1% ammonia); gradient: B 40%; flow rate: 50mL / min; back pressure: 100bar; column temperature: 38 ° C; detection ultraviolet wavelength: 220nm) to obtain optically pure compound 1-16 (10 mg , white solid, yield: 71%) and optically pure compound 2-1 (10 mg, white solid, yield: 71%). The absolute structure of 1-16 was confirmed by single crystal X-ray. Example 3, 4 The first step (synthesis of 3-1)

Compound 1-12 (100 mg) was dissolved in 4 mL of ethyl acetate. ethyl acetate (4 mL, 4M) was evaporated. Form), the product was directly subjected to the next reaction without purification. The second step (synthesis of 3-2)

Compound 3-1 (100 mg, 0.26 mmol), compound 1-14 (58 mg, 0.28 mmol), HATU (150 mg, 0.39 mmol) and DIEA (124 mg, 0.96 mmol) were dissolved in 5 mL of DMF. After stirring at room temperature for 3 hours, the reaction solution was poured into a brine solution and extracted with ethyl acetate (10 mL×3). The organic phase was combined and washed with water (10 mL×2) and saturated sodium chloride solution (10 mL×2) Wash, dry, filter and concentrate to give a crude product. The crude product was isolated by preparative HPLC to afford compound 3-2 (30 mg, white solid, yield: 20%). ¹ H NMR (400 MHz, MeOD) δ = 8.14 (br. s., 1H), 8.00 - 7.61 (m, 4H), 7.49 (br. s., 0.5H), 7.33 (dd, J = 8.0, 17.8 Hz, 1H), 7.12 (br. s., 1H), 6.56 (br. s., 0.5H), 5.00 - 4.83 (m, 1H), 4.48 (br. s., 3H), 3.88 - 3.62 (m , 1H), 2.45 - 2.34 (m, 3H), 2.05 - 1.56 (m, 5H), 1.42-1.35 (m, 3H) The third step (synthesis of 3-3 and 4-1)

The compound racemic product 3-2 (30 mg) was separated via SFC (isolation method: instrument model: MG II preparative SFC; separation column: ChiralPak IC, 250 x 30 mm I.D.; mobile phase: A: CO ₂ , B: ethanol (0.1% ammonia); gradient: B 50%; flow rate: 45 mL / min; back pressure: 100 bar; column temperature: 38 ° C; detection wavelength: 220 nm) to obtain optically pure compound 3-3 (12 mg, white Solid, Yield: 80%) and optically pure compound 4-1 (12 mg, white solid, yield: 80%). (3-3 and 4-1 are a pair of enantiomers, the relative structure of which is a hypothetical structure, and the absolute structure is not confirmed). Example 5, 6 The first step (synthesis of 5-2)

Compound 1-12 (120 mg, 0.32 mmol), compound 5-1 (77 mg, 0.38 mmol), HATU (182 mg, 0.48 mmol) and DIEA (124 mg, 0.96 mmol) were dissolved in 5 mL DMF at room temperature After stirring for 3 hours, the reaction solution was poured into a brine solution and extracted with ethyl acetate (10 mL×3). The organic phase was combined and washed with water (10 mL×2) and saturated sodium chloride solution (10 mL×2). Drying over anhydrous sodium sulfate, EtOAc (EtOAc m.) ¹ H NMR (400MHz, METHANOL-d ₄ ) = 8.83 (br. s., 2H), 8.17-8.01 (m, 2H), 7.49-7.33 (m, 3H), 6.86 (dd, J = 3.5, 9.0 Hz , 1H), 6.41 (br. s., 1H), 4.63 (br. s., 1H), 4.43 (br. s., 1H), 4.11 (br. s, 1H), 3.79 (br. s., 1H), 2.52-2.48 (m, 2H), 2.35-2.11 (m, 1H), 2.01-1.95 (m, 3H), 1.90 - 1.67 (m, 3H), 1.63 - 1.43 (m, 1H), 1.29 - 1.20 (m, 2H) The second step (synthesis of 5-3 and 6-1)

The compound racemic product 5-2 (24 mg) was separated via SFC (isolation method: instrument model: MG II preparative SFC; separation column: ChiralPak IC, 250 x 30 mm I.D.; mobile phase: A: CO ₂ , B: ethanol (0.1% ammonia); gradient: B 45%; flow rate: 40 mL / min; back pressure: 100 bar; column temperature: 38 ° C; detection wavelength: 220 nm) to obtain optically pure compound 5-3 (8 mg, white Solid) and 6-1 (8 mg, white solid), total yield of two compounds: 67%. Examples 7, 8 The first step (synthesis of 7-1)

Compound 3-1 (100 mg, 0.26 mmol), compound 5-1 (58 mg, 0.28 mmol), HATU (150 mg, 0.39 mmol) and DIEA (124 mg, 0.96 mmol) were dissolved in 5 mL DMF at room temperature After stirring for 3 hours, the reaction solution was poured into a brine solution and extracted with ethyl acetate (10 mL×3). The organic phase was combined and washed with water (10 mL×2) and saturated sodium chloride solution (10 mL×2) Dry, filtered and concentrated to give a crude material. The crude product was isolated by preparative HPLC to afford compound 7-1 (30 mg, white solid, yield: 20%). ¹ H NMR (400 MHz, MeOD) δ = 8.78 (dd, J = 4.9, 9.7 Hz, 2H), 8.17 (d, J = 8.2 Hz, 0.5H), 8.11 (d, J = 7.9 Hz, 0.5H) , 8.01 (d, J = 3.1 Hz, 0.5H), 7.75 (br. s., 0.5H), 7.57 - 7.50 (m, 0.5H), 7.43 (d, J = 8.2 Hz, 0.5H), 7.38 - 7.31 (m, 2H), 7.26 (s, 0.4H), 7.13 (s, 0.6H), 6.86 (dd, J = 3.5, 9.0 Hz, 0.5H), 6.36 (dd, J = 3.5, 9.0 Hz, 0.5 H), 4.77 - 4.72 (m, 0.5H), 4.21 - 4.11 (m, 1.5H), 3.78 (br. s., 1H), 2.52 (br. s., 1H), 2.46 (s, 1.5H) , 2.35 (s, 1.5H), 2.09 - 1.95 (m, 2H), 1.91 - 1.37 (m, 7H) The third step (synthesis of 7-2 and 8-1)

The compound racemic product 7-1 (30 mg) was separated via SFC (isolation method: instrument model: MG II preparative SFC; separation column: ChiralPak AS, 250 x 30 mm I.D.; mobile phase: A: CO ₂ , B: ethanol (0.1% ammonia); gradient: B 15%; flow rate: 60 mL / min; back pressure: 100 bar; column temperature: 38 ° C; detection wavelength: 220 nm) to obtain optically pure compound 7-2 (12 mg, white Solid, Yield: 80%) and optically pure compound 8-1 (12 mg, white solid, yield: 80%). (7-2 and 8-1 are a pair of enantiomers, and the corresponding structure is a hypothetical structure, and the absolute structure is not confirmed). The first step (synthesis of 9-1)

The compound racemic product 1-11 (280 mg) was separated via SFC (isolation method: instrument model: MG II preparative SFC (SFC-1); separation column: ChiralPak AD, 250 x 30 mm I.D.; mobile phase :A:CO ₂ ,B:ethanol (0.1% ammonia); gradient: B 25%; flow rate: 60 mL / min; back pressure: 100 bar; column temperature: 38 ° C; detection wavelength: 220 nm) to obtain optically pure compound 9-1 (100 mg, white solid, yield: 71%). The second step (synthesis of 9-2)

Compound 9-1 (120 mg) was dissolved in 4 mL of ethyl acetate. ethyl acetate (4 mL, 4M) Form), the product was directly subjected to the next reaction without purification. The third step (synthesis of 9-4)

Compound 9-2 (120 mg, 0.32 mmol), compound 9-3 (77 mg, 0.38 mmol), HATU (182 mg, 0.48 mmol) and DIEA (124 mg, 0.96 mmol) were dissolved in 5 mL of DMF. After stirring for 3 hours, the reaction solution was poured into an aqueous solution of brine and extracted with ethyl acetate (10 mL×3). The organic phase was combined and washed with water (10 mL×2) and saturated sodium chloride solution (10 mL×2) Drying over anhydrous sodium sulfate, EtOAc (EtOAc)EtOAc. ¹ H NMR (400 MHz, MeOD) δ = 8.20-7.98 (m, 3H), 7.85 - 7.72 (m, 1H), 7.71 - 7.50 (m, 2H), 7.48 - 7.17 (m, 1H), 7.03 - 6.75 (m, 1H), 4.87-4.66 (m, 1H), 4.54 - 4.36 (m, 1H), 4.31-4.05 (m, 1H), 3.86 - 3.55 (m, 1H), 2.14 (br. s., 1H ), 2.08 - 1.95 (m, 1H), 1.88 (td, J = 7.2, 19.8 Hz, 2H), 1.77 (dd, J = 11.3, 18.1 Hz, 2H), 1.68 - 1.54 (m, 1H), 1.53 - 1.32 (m, 2H) Example 10 The first step (synthesis of 10-2)

Compound 9-2 (120 mg, 0.32 mmol), compound 10-1 (77 mg, 0.38 mmol), HATU (182 mg, 0.48 mmol) and DIEA (124 mg, 0.96 mmol) were dissolved in 5 mL of DMF. After stirring for 3 hours, the reaction solution was poured into an aqueous solution of brine and extracted with ethyl acetate (10 mL×3). The organic phase was combined and washed with water (10 mL×2) and saturated sodium chloride solution (10 mL×2) Drying over anhydrous sodium sulfate, EtOAc (EtOAc m.) ¹ H NMR (400MHz, CHLOROFORM-d) = 8.11 - 7.90 (m, 1H), 7.81 - 7.56 (m, 2H), 7.49 - 7.38 (m, 2H), 7.35 (d, J = 8.8 Hz, 1H), 6.77 (br. s., 1H), 6.42 (d, J = 6.0 Hz, 1H), 4.97 (br. s., 0.3H), 4.82 (br. s., 0.7H), 4.40 (br. s. , 0.5H), 4.14 (br. s., 1H), 4.06 (br. s., 0.6H), 4.00 (d, J = 10.3 Hz, 0.5H), 3.74 (br. s., 0.4H), 2.76 (br. s., 1H), 2.12 (br. s., 0.5H), 2.06 - 1.86 (m, 2.5H), 1.85 - 1.67 (m, 2H), 1.62 (br. s., 1H), 1.65 - 1.56 (m, 2H), 1.45 (br. s., 1H), 1.12 (br. s., 1H), 0.67 (d, J = 6.3 Hz, 1H) Example 11

Example 11 Referring to the synthetic route of Example 10, the reagent 10-1 used was replaced by 11-1: Purification by preparative HPLC gave the product 11-2 (24 mg, white solid, yield: 25%). ¹ H NMR (400MHz, CHLOROFORM-d) = 8.55 (br. s., 1H), 8.42 (br. s., 0.5H), 8.03 - 7.85 (m, 1H), 7.80 - 7.63 (m, 2H), 7.57 (d, J = 7.5 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.34 - 7.28 (m, 1.5H), 7.23 (d, J = 5.0 Hz, 1H), 6.84 - 6.63 ( m, 1H), 4.50 (t, J = 9.5 Hz, 1H), 4.32 (dd, J = 5.8, 10.8 Hz, 1H), 3.89 (br. s., 2H), 2.40 (s, 3H), 2.20 - 1.93 (m, 4H), 1.84 (dt, J = 7.3, 13.4 Hz, 1H), 1.72 (d, J = 8.5 Hz, 2H), 1.52 (d, J = 11.5 Hz, 1H), 1.48 - 1.35 (m , 1H) Example 12

Example 12 refers to the synthetic route of Example 10, in which reagent 10-1 is replaced by 12-1: Purification by preparative HPLC gave the product 12-2 (8 mg, white solid, yield: 9%). ¹ H NMR (400MHz, CHLOROFORM-d) =7.96 (d, J =2.5 Hz, 1H), 7.57 - 7.43 (m, 2H), 7.42 - 7.30 (m, 3H), 7.30 - 7.23 (m, 2.5H) , 7.20 (s, 1H), 7.09 (d, J = 8.0 Hz, 1H), 6.26 (dd, J = 3.5, 9.0 Hz, 0.5H), 4.94 - 4.71 (m, 1H), 4.09 - 3.97 (m, 1H), 3.96 - 3.79 (m, 1H), 3.61 (d, J =7.0 Hz, 1H), 2.40 (s, 1H), 1.99 - 1.89 (m, 2.5H), 1.86 - 1.59 (m, 2.5H) , 1.57 - 1.24 (m, 4H), 1.23 - 1.09 (m, 1H), 0.99 - 0.87 (m, 1H) Example 13

Example 13 refers to the synthetic route of Example 10, in which reagent 10-1 is replaced by 13-1: Purification by preparative HPLC gave the product 13-2 (37 mg, white solid, yield: 32%). ¹ H NMR (400MHz, CHLOROFORM-d) = 8.64 (br. s., 2H), 8.13 - 7.85 (m, 1H), 7.85 - 7.53 (m, 2H), 7.40 - 7.33 (m, 1.5H), 7.40 - 7.29 (m, 0.5H), 7.24 (br. s., 1H), 7.17 (d, J = 7.5 Hz, 1H), 6.76 (dd, J = 3.5, 9.0 Hz, 0.5H), 6.27 (dd, J = 3.5, 9.0 Hz, 0.5H), 4.95 - 4.74 (m, 1H), 4.12 - 3.87 (m, 2H), 3.64 - 3.44 (m, 1H), 2.44 (s, 1H), 2.11 (d, J =6.5 Hz, 1H), 2.07 - 1.88 (m, 2H), 1.88 - 1.72 (m, 2H), 1.72 - 1.63 (m, 1H), 1.62 - 1.42 (m, 3H), 1.41 - 1.29 (m, 1H ), 1.29 - 0.98 (m, 1H) Example 14

Example 14 Referring to the synthetic route of Example 10, the reagent 10-1 used was replaced by 14-1: Purification by preparative HPLC gave the product 14-2 (19 mg, pale yellow solid, yield: 20%). ¹ H NMR (400MHz, CHLOROFORM-d) = 8.04 - 7.90 (m, 1H), 7.89 - 7.63 (m, 2H), 7.34 - 7.26 (m, 1H), 7.23 (d, J =8.0 Hz, 1.5H) , 7.15 - 6.93 (m, 1.5H), 6.80-6.76 (m, 0.5H), 6.32-6.30 (m, 0.5 H), 4.99-4.90 (m, 1H), 4.49-4.35 (m, 1H), 4.19 -4.03 (m, 1H) 3.87 - 3.68 (m, 1H), 2.01 -1.86 (m, 6H), 1.70 - 1.38 (m, 2.5H), 1.36 - 1.05 (m, 0.5H) Example 15

Example 15 Referring to the synthetic route of Example 10, the reagent 10-1 used was changed to 15-1: Purification by preparative HPLC gave the product 15-2 (17 mg, pale yellow solid, yield: 18%). ¹ H NMR (400MHz, CHLOROFORM-d) = 8.01 (br. s., 1H), 7.94 - 7.70 (m, 2H), 7.64 (d, J =8.0 Hz, 1H), 7.42 - 7.23 (m, 2H) , 6.77 (d, J = 6.3 Hz, 1H), 6.59 - 6.24 (m, 1H), 4.99 (d, J = 17.1 Hz, 1H), 4.52 - 4.32 (m, 1H), 4.25 - 4.04 (m, 1H) ), 3.92 - 3.44 (m, 1H), 2.53 - 2.10 (m, 1H), 2.09 - 1.76 (m, 4H), 1.68 (br. s., 1H), 1.61 - 1.38 (m, 2H), 1.37 - 0.62 (m, 1H) Example 16

Example 16 refers to the synthetic route of Example 10, in which reagent 10-1 is replaced by 16-1: Purification by preparative HPLC gave the product 16-2 (6.5 mg, white solid, yield: 1.5%). ¹ H NMR (400MHz, CHLOROFORM-d) = 8.30 - 7.72 (m, 2H), 7.71 - 7.52 (m, 1H), 7.52 - 7.37 (m, 1H), 7.35 - 7.14 (m, 3H), 6.78 - 6.38 (m, 1H), 4.94 - 4.66 (m, 1H), 4.53 - 4.21 (m, 1H), 4.08 (br. s., 1H), 3.83 - 3.58 (m, 1H), 2.53 - 2.40 (m, 0.5 H), 1.90-1.82 (m, 1.5H), 1.81 - 1.45 (m, 5.5H), 1.27 (br. s., 0.5H), 1.0-0.91 (m, 1H) Example 17

Example 17 Referring to the synthetic route of Example 10, the reagent 10-1 used was replaced by 17-1: Purification by preparative HPLC gave the product 17-2 (4.3 mg, white solid, yield: 3.5%). ¹ H NMR (400MHz, CHLOROFORM-d) = 8.76 (d, J = 4.5 Hz, 1.5H), 8.39 - 8.12 (m, 1H), 7.96 (br. s., 1H), 7.34 (t, J = 6.7 Hz, 0.5H), 7.30 - 7.26 (m, 1H), 7.19 (br. s., 1H), 7.16 - 6.84 (m, 2H), 6.74 (d, J = 5.8 Hz, 0.5H), 6.29 (br .s., 0.5H), 5.08 - 4.83 (m, 1H), 4.48 - 4.15 (m, 1.5H), 4.14 - 4.04 (m, 0.5H), 3.89 (br. s., 0.5H), 3.78 - 3.63 (m, 0.5H), 2.27 - 2.06 (m, 2H), 2.03 - 1.93 (m, 1H), 1.92 - 1.81 (m, 1.5H), 1.79 - 1.59 (m, 2H), 1.57 - 1.41 (m , 1.5H), 1.25 (br. s., 1H) Example 18

Example 18 refers to the synthetic route of Example 10, in which reagent 10-1 is replaced by 18-1: Purification by preparative HPLC gave the product 18-2 (4.3 mg, white solid, yield: 9.5%). ¹ H NMR (400MHz, CHLOROFORM-d) = 8.94 - 8.74 (m, 1H), 8.65 (br. s., 1H), 8.39 - 8.26 (m, 1.5H), 7.70 - 7.42 (m, 0.5H), 7.36- 7.25 (m, 1H), 7.14 (br. s., 1H), 6.92-6.8 (m, 0.5H), 6.79 (d, J = 19.3 Hz, 1H), 5.98 (br. s., 0.5H ), 5.15 - 4.97 (m, 1H), 4.70 - 4.38 (m, 1H), 4.26 - 4.07 (m, 1.6H), 3.80 (br. s., 0.4H), 2.52 - 2.32 (m, 1H), 2.29 - 2.18 (m, 2H), 2.11 - 1.92 (m, 1H), 1.91 - 1.81 (m, 2H), 1.62 - 1.35 (m, 3H) Example 19

Example 19 Referring to the synthetic route of Example 10, the reagent 10-1 used was changed to 19-1: Purification by preparative HPLC gave the product 19-2 (29 mg, white solid, yield: 7%). ¹ H NMR (400MHz, CHLOROFORM-d) = 8.28 - 7.90 (m, 1H), 7.85 - 7.69 (m, 1H), 7.64 - 7.47 (m, 1.5H), 7.46 - 7.38 (m, 1H), 7.36 - 7.28 (m, 1H), 7.25 - 7.21 (m, 1.5H), 6.76 (dd, J = 3.3, 9.0 Hz, 0.5H), 6.36 (dd, J = 3.4, 8.9 Hz, 0.5H), 4.85 - 4.69 (m, 1H), 4.57 - 4.20 (m, 1H), 4.06 (d, J = 4.5 Hz, 1H), 3.77 - 3.57 (m, 1H), 2.24 - 1.99 (m, 1H), 1.97 - 1.78 (m , 2.5H), 1.76 - 1.52 (m, 4H), 1.46 (d, J = 8.0 Hz, 1.5H) Example 20

Example 20 refers to the synthetic route of Example 10, in which reagent 10-1 is replaced by 20-1: Purification by preparative HPLC gave the product 20-2 (51 mg, white solid, yield: 55%). ¹ H NMR (400MHz, CHLOROFORM-d) = 8.08 - 7.93 (m, 1H), 7.87 - 7.60 (m, 2H), 7.56 - 7.42 (m, 1H), 7.34 - 7.24 (m, 2H), 7.22 - 7.16 (m, 1H), 6.79 (d, J = 5.3 Hz, 0.4H), 6.42 - 6.27 (m, 1.6H), 4.97 - 4.73 (m, 1H), 4.50 -3.91 (m, 2H), 3.77 (d , J = 6.0 Hz, 0.6H), 3.58 (br. s., 0.4H), 2.43 (br. s., 1H), 2.26 - 2.03 (m, 1H), 2.00 - 1.88 (m, 3H), 1.85 - 1.65 (m, 3H), 1.59 (d, J = 6.0 Hz, 2H), 1.51 - 1.37 (m, 2H) Example 21 The first step (synthesis of 21-2)

Compound 9-2 (50 mg, 0.18 mmol) was dissolved in 2 mL dichloromethane and triethylamine (56 mg, 0.55 mmol) and compound 21-1 (48 mg, 0.28 mmol). After stirring at room temperature for 2 hours, the solvent was evaporated to dryness crystals crystals crystals crystals ¹ H NMR (400MHz, CHLOROFORM-d) = 7.96 (br. s., 1H), 7.50 - 7.18 (m, 3H), 7.16 - 6.94 (m, 2H), 6.78- 6.19 (m, 1H), 5.14 - 4.80 (m, 1H), 4.69 - 4.23 (m, 1.5H), 4.20 - 3.86 (m, 1.5H), 2.39 (br. s., 1H), 2.28 - 2.09 (m, 3H), 2.09 - 1.92 ( m, 3H), 1.85 (br. s., 1H), 1.75 (br. s., 1H), 1.64 (s, 1H), 1.52 (br. s., 1H), 1.44 - 1.08 (m, 1H) Example 22

Compound 9-2 (50 mg, 0.18 mmol) was dissolved in 2 mL dichloromethane and triethylamine (56 mg, 0.55 mmol) and compound 22-1 (53 mg, 0.28 mmol). After stirring at room temperature for 2 hours, the solvent was evaporated to give a crude material. The crude product was purified by preparative EtOAc EtOAc EtOAc ¹ H NMR (400MHz, CHLOROFORM-d) = 7.96 (d, J = 2.8 Hz, 1H), 7.78 - 7.54 (m, 2H), 7.34 - 7.19 (m, 3H), 6.63 (dd, J = 3.4, 8.9 Hz, 1H), 4.48 - 4.24 (m, 3H), 4.21 - 4.07 (m, 1H), 2.35 (s, 3H), 2.03 (d, J = 6.0 Hz, 1H), 1.97 - 1.69 (m, 4H) , 1.68 - 1.60 (m, 2.6H), 1.54 - 1.45 (m, 1.5H) Example 23 The first step (synthesis of 23-1)

Compound 1-7 (48 g) was dissolved in 50 mL of ethyl acetate. ethyl acetate (150 mL, 4M) Form), the product was directly subjected to the next reaction without purification. The second step (synthesis of 23-2)

Compound 23-1 (33 g, 150 mmol) was dissolved in dichloromethane (300 mL). EtOAc (EtOAc, EtOAc) After half an hour, the reaction solution was allowed to warm to room temperature and stirred overnight. The reaction mixture was poured into water and extracted with dichloromethane (300 mL×3). The organic phase was combined, washed with water (100 mL×2), saturated sodium chloride solution (100 mL×2) and dried over anhydrous sodium sulfate. Filtration and concentrating gave a crude material which was purified eluting with EtOAc (EtOAc: EtOAc: EtOAc The third step (synthesis of 23-3)

Compound 23-2 (35 g) was isolated by preparative HPLC to afford product 23-3 (22 g, 62.8%). The fourth step (synthesis of 23-4)

Compound 23-3 (5 g, 15.75 mmol) was dissolved in 100 mL of methanol, and then wet Pd(OH) 2 (500 mg, 5%) was added and stirred for 16 hours under hydrogen atmosphere. The reaction mixture was filtered and evaporated to give crystal crystal crystal crystal crystal crystal crystal The fifth step (synthesis of 23-5)

Compound 23-4 (8 g, 43.7 mmol), compound 5-1 (11.2 g, 52.4 mmol), HATU (24.9 g, 65.6 mmol) and DIEA (16.9 g, 131.1 mmol) were dissolved in 200 mL of THF. After stirring at room temperature for 16 hours, the reaction solution was poured into an aqueous solution of brine and extracted with ethyl acetate (100 mL×3). The organic phase was combined with water (50 mL×2) and saturated sodium chloride solution (50 mL×2) Washed, dried over anhydrous sodium sulfate, filtered, EtOAcjHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH :78%). The sixth step (synthesis of 23-6)

Compound 23-5 (950 mg, 2.5 mmol) was dissolved in THF (25 mL) and EtOAc (EtOAc) The reaction was stirred at the current temperature for 1 hour. After adding 20 mL of anhydrous THF, the reaction was quenched by dropwise addition of 0.1 mL of water, 0.1 mL of 15% sodium hydroxide solution and 0.3 mL of water, then dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give product 23-6 ( 800 mg, pale yellow solid, yield: 96%). The seventh step (synthesis of 23-8)

Compound 23-6 (80 mg, 0.237 mmol) was dissolved in 5 mL DMF and NaH (38 mg, 60%, The reaction was stirred at the current temperature for 0.5 h then compound 23-7 (46 mg, 0.474 mmol). The reaction solution was stirred at room temperature for 16 hours, poured into a brine solution and extracted with ethyl acetate (20 mL×3). The organic phase was combined with water (10 mL×2) and saturated sodium chloride solution (10 mL×2) After washing, it was dried over anhydrous sodium sulfate, filtered, and evaporated, evaporated,,,,,,,,,,,,,,,,,,,,,,,,,,, ¹ H NMR (400MHz, CHLOROFORM-d) = 8.75 (br. s., 2H), 8.22 - 8.06 (m, 2H), 7.58 - 7.46 (m, 1H), 7.28 (d, J =8.0 Hz, 1H) , 7.23 - 7.05 (m, 2H), 6.88 - 6.76 (m, 1H), 6.34 (br. s., 1H), 5.01 (d, J = 6.5 Hz, 1H), 4.65 - 4.37 (m, 1H), 4.16 (d, J = 6.3 Hz, 1H), 3.94 - 3.75 (m, 1H), 2.41 (s, 1H), 2.21 (d, J =7.0 Hz, 1H), 1.96 - 1.77 (m, 5H), 1.54 - 1.45 (m, 2H), 1.33-0.77 (m, 3H) Example 24 The first step (synthesis of 24-2)

Compound 23-6 (80 mg, 0.237 mmol) was dissolved in 5 mL DMF and NaH (38 mg, 60%, After the reaction mixture was stirred at the current temperature for 0.5 hour, compound 24-1 (53 mg, 0.474 mmol) was added. The reaction solution was stirred at room temperature for 16 hours, poured into a brine solution and extracted with ethyl acetate (20 mL×3). The organic phase was combined with water (10 mL×2) and saturated sodium chloride solution (10 mL×2) The mixture was washed with EtOAc EtOAc. ¹ H NMR (400MHz, CHLOROFORM-d) = 8.75 (br. s., 2H), 8.20 - 8.07 (m, 1H), 7.98 - 7.88 (m, 1H), 7.41 - 7.28 (m, 1H), 7.23 - 7.08 (m, 3H), 6.71- 6.25 (m, 1H), 5.01 (d, J = 6.3 Hz, 1H), 4.64 - 4.30 (m, 1H), 4.12 (d, J = 6.8 Hz, 1H), 3.92 - 3.75 (m, 1H), 2.41 (s, 1.5H), 2.29 - 2.16 (m, 4H), 2.01 - 1.75 (m, 6H), 1.56 - 1.44 (m, 1.5H), 1.30 - 1.21 (m, 1.5H), 0.98 (d, J = 6.8 Hz, 0.5H) Example 25 The first step (synthesis of 25-2)

Example 25 Referring to the synthetic route of Example 24, the reagent 24-1 used was changed to 25-1: Purification via TLC plate gave product 25-2 (33.72 mg, white solid, yield: 22%). ¹ H NMR (400MHz, CHLOROFORM-d) = 8.74 (br. s., 2H), 8.16 (dd, J = 7.7, 18.2 Hz, 1H), 7.89 (br. s., 1H), 7.37 - 7.25 (m , 2H), 7.24 - 7.12 (m, 2H), 5.01 (br. s., 1H), 4.84 - 4.36 (m, 1H), 4.21 (br. s., 1H), 3.80 (d, J = 19.8 Hz , 1H), 2.42 (br. s., 2H), 2.09 (br. s., 2H), 1.86-1.8 (m, 3H), 1.68-1.60 (m, 1H), 1.60 - 1.43 (m, 2H) , 1.35 - 1.13 (m, 2H), Example 26 The first step (synthesis of 26-1)

Compound 1-7 (4.0 g, 14.13 mmol) was dissolved in 30 mL of tetrahydrofuran, and LDA (14.4 mL, 28.26 mmol) was slowly added dropwise at 0 ° C, and stirred at 0 ° C for 1 hour. The temperature was maintained at 0 ° C, and the compound NFSI (5.3 g, 16.96 mmol) was added to the reaction. After the addition was completed, the temperature was slowly raised to room temperature, and the reaction was stirred overnight at room temperature. The reaction solution was poured into aq. EtOAc (30 mL). EtOAc (EtOAc m. Washed with a saturated sodium chloride solution (40 mL × 2), dried over anhydrous sodium sulfate, filtered and evaporated to give a crude crystals. Purification afforded product 26-1 (1.5 g, yellow oilyield, yield: 40%) LC/MS: 245.9 (M-56+H ⁺ ), 323.9 (M+Na ⁺ ) synthesis)

Compound 26-1 (1.8 g, 6.0 mmol) was dissolved in 30 mL of tetrahydrofuran, and LAH (500 mg, 13.15 mmol) was added in small portions at 0 ° C. After the addition, the temperature was raised to room temperature and allowed to react overnight at room temperature. . 0.5 mL of water, 0.5 mL of 15% aqueous sodium hydroxide solution and 1.5 mL of water were successively added to the reaction solution, and a small amount of magnesium sulfate was added thereto, and the mixture was stirred for 10 minutes, filtered, and the filtrate was spun to obtain the product 26-2. The product was not purified. Go directly to the next step. The third step (synthesis of 26-3)

Compound 26-2 (1.5 g, 5.88 mmol) was dissolved in 20 mL of DMF. NaH (800 mg, 20.0 mmol) was added in small portions at 0 ° C, kept at constant temperature, stirred for 30 minutes, then dripped Add compound 1-9 (676 mg, 5.88 mmol), add to room temperature, react at room temperature for 10 hours, pour the reaction solution into 30 mL of water, and add 30 mL of saturated sodium chloride solution to acetic acid The organic phase was extracted with water (30 mL×2), saturated sodium chloride solution (30 mL×2), dried over anhydrous sodium sulfate, filtered and purified by column chromatography :ethyl acetate = 50:1) Purification afforded product 26-3 (500 mg,yield: 25%). LC/MS: 254.9 (M-56+H ⁺ ), 254.9 (M-Boc+H ⁺ ), 354.9 (M+H ⁺ ) Step 4 (Synthesis of 26-4)

Compound 26-3 (150 mg) was dissolved in 4 mL EtOAc /EtOAcEtOAcEtOAcEtOAcEtOAc Form), the product was directly subjected to the next reaction without purification. The fifth step (synthesis of 26-5)

Compound 26-4 (120 mg, 0.37 mmol), compound 5-1 (94 mg, 0.38 mmol), HATU (209 mg, 0.55 mmol) and DIEA (143 mg, 0.96 mmol) were dissolved in 5 mL of DMF. After stirring at room temperature for 3 hours, the reaction solution was poured into a brine solution and extracted with ethyl acetate (10 mL×3). The organic phase was combined with water (10 mL×2) and saturated sodium chloride solution (10 mL×2) Washed, dried over anhydrous sodium sulfate, filtered andEtOAc ¹ H NMR (400MHz, METHANOL-d4) = 8.91 - 8.78 (m, 2H), 8.21 - 8.00 (m, 2H), 7.59 - 7.40 (m, 2H), 7.38 - 7.17 (m, 2H), 6.92 (dd , J=3.8, 9.3 Hz, 1H), 5.17 - 5.01 (m, 1H), 4.81 - 4.58 (m, 2H), 4.34 (br. s., 1H), 2.64 - 2.36 (m, 3H), 2.29 - 2.09 (m, 2H), 2.01 - 1.67 (m, 6H) Example 27 The first step (synthesis of 27-1)

The compound 23-5 (190 mg) was dissolved in 10 mL of THF, and 10 mL of a 0.48% aqueous solution of LiOH was added thereto, and the mixture was heated to reflux for 3 hours. Dilute hydrochloric acid was added dropwise to weakly acidic, and extracted with ethyl acetate. The product 27-1 (160 mg, 94%) was taken to the next step without purification. The second step (synthesis of 27-3)

Compound 27-1 (105.4 mg, 0.3 mmol), compound 27-2 (65.5 mg, 0.6 mmol), HATU (171 mg, 0.45 mmol) and DIEA (0.157 mL, 0.9 mmol) were dissolved in 5 mL THF. After stirring at room temperature for 16 hours, the reaction solution was poured into an aqueous solution of brine and extracted with ethyl acetate (10 mL×3), and the organic phase was combined with water (5 mL×2) and saturated sodium chloride solution (5 mL×2) It was washed, dried over anhydrous sodium sulfate, filtered, evaporated, evaporated, ¹ H NMR (400MHz, CHLOROFORM-d) = 10.63 (br. s., 0.5H), 9.23 (br. s., 1H), 8.76 (br. s., 0.5H), 8.38 (br. s., 1H), 8.20 (br. s., 1H), 7.35 (d, J = 8.0 Hz, 1.5H), 7.14 - 6.92 (m, 5H), 6.76 - 6.54 (m, 1.5H), 5.36 - 5.22 (m , 1H), 3.99 (br. s., 0.5H), 3.83 (br. s., 0.5H), 2.80 (s, 5H), 2.46 - 2.42 (m, 3H), 2.23 (d, J = 7.5 Hz , 1H), 2.11 - 1.96 (m, 3H) Example 28 The first step (synthesis of 28-1)

Compound 27-3 (88 mg, 0.2 mmol) and triphenylphosphine (52.4 mg, 0.2 mmol) were dissolved in THF (25 mL) and then 2 mL DIDA (40.4 mg, 0.2 mmol) in THF. The reaction solution was heated to reflux for 3 hours, poured into a brine solution and extracted with ethyl acetate (10 mL×3). The organic phase was combined and washed with water (10 mL×2) and saturated sodium chloride solution (10 mL×2). Drying over anhydrous sodium sulfate, EtOAc (EtOAc m.) ¹ H NMR (400MHz, CHLOROFORM-d) = 10.51 (br. s., 0.4H), 10.03 (br. s., 0.1H), 9.15 (s, 1H), 8.74 (br. s., 1H), 8.39 (br. s., 1H), 8.26 - 8.10 (m, 1H), 7.41 - 7.30 (m, 1.5H), 7.05 (br. s., 1.5H), 6.92 (d, J = 8.5 Hz, 1.5 H), 6.74 (br. s., 1H), 5.24 (br. s., 1H), 4.99 - 4.81 (m, 2H), 4.01 (br. s., 0.6H), 3.78 (br. s., 0.4H), 2.78 (br. s., 1H), 2.43 (br. s., 4H), 2.25 (br. s., 1H), 2.11 - 1.93 (m, 3H), 1.81 (br. s., 1H) Example 29 The first step (synthesis of 29-1)

Compound 23-5 (5 g) was separated via SFC (isolation method: instrument model: MG II preparative SFC (SFC-1); separation column: ChiralPak OD, 250 x 30 mm I.D.; mobile phase: A: CO ₂ , B: ethanol (0.1% ammonia); gradient: B 30%; flow rate: 55mL / min; back pressure: 100bar; column temperature: 38 ° C; detection wavelength: 220 nm) to obtain palm pure compound 29-1 (2 g, White solid, yield: 80%). The second step (synthesis of 29-2)

Compound 29-1 (1.3 g, 3.426 mmol) was dissolved in 25 mL THF and EtOAc (100 mg, &lt The reaction was stirred at the current temperature for 1 hour. After adding 20 mL of anhydrous THF, the reaction was quenched by dropwise addition of 0.1 mL of water, 0.1 mL of 15% sodium hydroxide solution and 0.3 mL of water, then dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give product 29-2 (1.1 g, pale yellow solid, yield: 96%). The third step (synthesis of 29-3)

Compound 29-2 (200 mg, 0.6 mmol) was dissolved in 10 mL DCM and then triethylamine (152 mg, 1.5 mmol) and MsCl (103 mg, 0.9 mmol). The reaction solution was stirred at room temperature for 2 hours, poured into a brine solution and extracted with dichloromethane (10 mL×3), and the organic phase was combined with water (10 mL×2) and saturated sodium chloride solution (10 mL×2) After washing, it was dried over anhydrous sodium sulfate, filtered, and then evaporated. The fourth step (synthesis of 29-5)

Compound 29-3 (98 mg, 0.237 mmol) and compound 29-4 (53 mg, 0.474 mmol) were dissolved in 5 mL DMF. The reaction solution was stirred at 80 ° C for 16 hours, poured into a brine solution and extracted with ethyl acetate (20 mL×3). The organic phase was combined with water (10 mL×2) and saturated sodium chloride solution (10 mL× 2) Washing, drying over anhydrous sodium sulfate, EtOAc (EtOAc m.) 1H NMR (400MHz, CHLOROFORM-d) = 8.76 (d, J=4.3 Hz, 1H), 8.70 (br. s., 1H), 8.16 (d, J=8.0 Hz, 0.5H), 8.10 (d, J =8.0 Hz, 0.5H), 7.31 (d, J=8.0 Hz, 0.5H), 7.17 (d, J=7.3 Hz, 1.5H), 7.10 (br. s., 1H), 6.98 - 6.88 (m, 3H), 6.57 (br. s., 1H), 5.00 (d, J=7.3 Hz, 0.6H), 4.92 (br. s., 0.4H), 4.26 (br. s., 0.6H), 4.04 ( Br. s., 0.4H), 3.84 (br. s., 1.5H), 3.66 (dd, J=6.0, 8.5 Hz, 0.5H), 2.41 (s, 2H), 2.17 (br. s., 0.5 H), 1.98 - 1.73 (m, 7H), 1.52 (d, J = 8.5 Hz, 1.5H), 1.25 (br. s., 1H) Example 30 The first step (synthesis of 30-2)

Compound 29-3 (98 mg, 0.237 mmol) and compound 30-1 (63 mg, 0.474 mmol) were dissolved in 5 mL DMF. The reaction solution was stirred at 80 ° C for 16 hours, poured into a brine solution and extracted with ethyl acetate (20 mL×3). The organic phase was combined with water (10 mL×2) and saturated sodium chloride solution (10 mL× 2) Washing, drying over anhydrous sodium sulfate, filtered, EtOAc EtOAc m. ¹ H NMR (400MHz, CHLOROFORM-d) = 8.75 (d, J = 3.8 Hz, 1H), 8.70 (br. s., 1H), 8.17 (d, J = 8.0 Hz, 0.6H), 8.12 (d, J = 7.8 Hz, 0.4H), 7.31 (d, J = 7.8 Hz, 0.5H), 7.21 (d, J = 8.0 Hz, 0.5H), 7.18 - 7.05 (m, 2.5H), 6.91 - 6.82 (m , 1H), 6.79 (br. s., 1.5H), 5.01 (d, J = 6.5 Hz, 0.5H), 4.92 (br. s., 0.5H), 4.32 (br. s., 0.6H), 4.12 (br. s., 0.4H), 4.03 - 3.68 (m, 2H), 2.41 (s, 2H), 2.21 (br. s., 1H), 2.02 (d, J =11.5 Hz, 2H), 1.94 - 1.78 (m, 4H), 1.61 - 1.48 (m, 2H), 1.25 (br. s., 1H) Example 31

Example 31 Referring to the synthetic route of Example 30, the reagent 30-1 used was changed to 31-1: Purification by preparative HPLC gave the product 31-2 (5.79 mg, white solid. ¹ H NMR (400MHz, CHLOROFORM-d) = 8.84 - 8.61 (m, 2H), 8.47-8.26 (m, 1H), 8.18 (d, J =8.0 Hz, 1H), 8.12 - 8.06 (m, 0.5H) , 8.02 (br. s., 0.5H), 7.37 (dd, J = 1.5, 8.5 Hz, 0.5H), 7.33 - 7.27 (m, 1.5H), 7.22 - 7.04 (m, 3H), 5.02 (d, J = 6.5 Hz, 1H), 4.40 (br. s., 0.5H), 4.17 - 4.06 (m, 0.5H), 3.92 (br. s., 1H), 3.80 (br. s., 0.5H), 3.74 (dd, J = 5.5, 8.5 Hz, 0.5H), 2.41 (s, 1.5H), 2.26 - 2.21 (m, 0.5H), 1.99 - 1.73 (m, 6H), 1.67 (br. s., 1.5 H), 1.51 (d, J = 9.5 Hz, 1.5H), 0.98 - 0.79 (m, 1H) Example 32

Example 31 Referring to the synthetic route of Example 30, the reagent 30-1 used was changed to 32-1: Purification by preparative HPLC gave the product 32-2 (7.32 mg, white. ¹ H NMR (400MHz, CHLOROFORM-d) = 8.75 (d, J = 4.5 Hz, 2H), 8.26 (d, J = 6.8 Hz, 1H), 7.87 (br. s., 2H), 7.36 (d, J =8.0 Hz, 1H), 7.20 (br. s., 2H), 6.60 (br. s., 2H), 4.75 (d, J =5.5 Hz, 1H), 4.29 (br. s., 1H), 3.90 (br. s., 2H), 2.45 (s, 3.5H), 2.07 (br. s., 3.5H), 1.77 (br. s., 1H), 1.63 (br. s., 2H), 1.52 ( d, J = 12.8 Hz, 1H), 1.34 (br. s., 1H) Example 33

Example 33 Referring to the synthetic route of Example 10, the reagent 10-1 used was changed to 33-1: Purification by preparative HPLC gave the product 33-2 (25 mg, pale yellow solid, yield: 29%). ¹ H NMR (400MHz, CHLOROFORM-d) = 8.87 - 8.68 (m, 1H), 8.68 - 8.48 (m, 1H), 8.30 - 7.89 (m, 2H), 7.58 - 7.40 (m, 1H), 7.34 (s , 1H), 7.33 - 7.22 (m, 2H), 7.18 (d, J = 7.8 Hz, 1H), 6.77 (dd, J = 3.0, 8.8 Hz, 0.4H), 6.30 (dd, J = 3.1, 8.9 Hz , 0.6H), 4.95 - 4.71 (m, 1H), 4.07 - 3.92 (m, 1H), 3.71 - 3.49 (m, 1H), 3.38 (br. s., 1H), 2.44 (s, 1H), 2.29 - 2.04 (m, 1H), 2.04 - 1.93 (m, 2H), 1.93 - 1.70 (m, 2H), 1.66-1.52 (m, 1H), 1.59 - 1.20 (m, 5H) Example 34

Example 34 refers to the synthetic route of Example 10, in which reagent 10-1 is replaced by 34-1: Purification by preparative HPLC gave the product 34-2 (30 mg, pale yellow solid, yield: 34.5%). ¹ H NMR (400MHz, CHLOROFORM-d) = 9.31 - 9.12 (m, 1H), 9.06 - 8.74 (m, 2H), 8.07 - 7.88 (m, 1H), 7.43 - 7.10 (m, 4H), 6.78 (dd , J = 3.4, 8.9 Hz, 0.4H), 6.28 (dd, J = 3.4, 8.9 Hz, 0.6H), 4.98 - 4.73 (m, 1H), 4.41 (br. s., 1H), 4.13 - 3.85 ( m, 1H), 3.69 - 3.44 (m, 1H), 2.45 (s, 1H), 2.33 - 2.06 (m, 1H), 2.04 - 1.93 (m, 3H), 1.93 - 1.73 (m, 2H), 1.68 ( Br. s., 1H), 1.60 - 1.51 (m, 1H), 1.50 - 1.23 (m, 3H) Example 35

Example 35 Referring to the synthetic route of Example 10, the reagent 10-1 used was changed to 35-1: Purification by preparative HPLC gave the product 35-2 (4.47 mg, white solid. ¹ H NMR (400MHz, CHLOROFORM-d) = 8.80 (br. s., 2H), 8.52 - 8.25 (m, 1H), 7.86 - 7.63 (m, 2H), 7.31 (t, J =8.2 Hz, 1H) , 7.26 - 7.18 (m, 2H), 6.75 (dd, J = 3.5, 9.0 Hz, 0.5H), 6.26 (br. s., 0.5H), 5.02 (br. s., 1H), 4.65 - 4.38 ( m, 1H), 4.28 - 3.98 (m, 1H), 3.78 (br. s., 1H), 2.27 - 2.10 (m, 1H), 2.06 - 1.79 (m, 3H), 1.59-1.56 (m, 4H) , 1.25 (br. s., 1H) Example 36

Example 36 Referring to the synthetic route of Example 10, the reagent 10-1 used was changed to 36-1: Purification by preparative HPLC gave the product 36-2 (25.32 mg, white solid ¹ H NMR (400MHz, CHLOROFORM-d) = 8.06 - 7.79 (m, 1H), 7.38 - 7.27 (m, 1H), 7.12 - 7.02 (m, 1H), 6.95 - 6.77 (m, 2H), 6.29 (br s., 1H), 5.09 - 4.93 (m, 1H), 4.54 (dd, J = 7.8, 10.5 Hz, 0.5H), 4.34 (dd, J = 7.7, 10.4 Hz, 0.5H), 4.22 - 4.14 ( m, 0.5H), 4.06 (br. s., 1H), 3.73 (br. s.,0.5H), 2.44 - 2.19 (m, 3H), 2.19 - 2.05 (m, 3H), 2.04 - 1.87 (m , 3H), 1.87 - 1.60 (m, 3H), 1.60 - 0.90 (m, 3H) Example 37

Example 37 Referring to the synthetic route of Example 10, the reagent 10-1 used was changed to 37-1: Purification by preparative HPLC gave product 37-2 (29.63 mg, m. ¹ H NMR (400MHz, CHLOROFORM-d) = 8.30 - 7.93 (m, 1H), 7.92 - 7.78 (m, 1H), 7.77 - 7.54 (m, 1H), 7.46 - 6.95 (m, 4H), 6.79 (dd , J = 3.5, 9.0 Hz, 0.5H), 6.33 (d, J = 6.3 Hz, 0.5H), 5.11 - 4.76 (m, 1H), 4.69 - 4.24 (m, 1H), 4.16 - 3.97 (m, 1H ), 3.89 - 3.55 (m, 1H), 2.42 (s, 1H), 2.27 - 1.94 (m, 3H), 1.92 - 1.70 (m, 3H), 1.63 (br. s., 1H), 1.56 - 1.39 ( m, 2H), 1.27 - 0.80 (m, 2H) Experimental Example 1: OX1/2R in vitro test Purpose:

The inhibitory effect of the compound on the OX1 and OX2 GPCR receptors was evaluated by measuring the intracellular calcium signal changes by FLIPR and using the IC50 values of the compounds as indicators. Experimental materials: Cell line: HEK293-OX1 and OX2 stably transfected cell line HEK293-OX1 cell culture medium (DMEM, Invitrogen #11960-044, 10% serum Gibco #10099141, L-Glutamine 1×, Gibco #25030, sodium pyruvate 1 ×, Gibco #11360, Geneticin 300 μg/ml, Gibco #10131) HEK293-OX2 cell culture medium (DMEM, Invitrogen #11960-044, 10% serum Gibco #10099141, L-Glutamine 1×, Gibco #25030, sodium pyruvate 1 ×, Gibco #11360, Geneticin 300 μg / ml, Gibco #10131, Plasticin 2 μg/ml, Invitrogen # R21001) Trypsin (Invitrogen, #25200-072) DPBS (Hyclone, #SH30028.01B) Fluo-4 AM, Invitrogen# F14202 F-127, Invitrogen # P3000MP Probenecid, Sigma # P8761 384 Cell Plate, Greiner # 781946 384 Compound Plate, Greiner # 781280 CO ₂ Incubator, Thermo #371 Centrifuge, Eppendorf #5810R Vi-cell Cell Counter, Beckman Coulter POD 810 Plate Assembler Fully automated microplate pretreatment system Labcyte FLIPR, Molecular Device. Experimental procedures and methods: a) Cell seeding (HEK293-OX1 and HEK293-OX2 cells)

1) 37 ° C water bath preheating medium, trypsin, DPBS. Aspirate the cell culture medium and wash it with 10 ml of PBS;

2) Add the pre-warmed trypsin to the culture flask, rotate the culture flask to evenly cover the flask with trypsin, and digest it in a 37 ° C, 5% CO2 incubator for 1-2 minutes;

3) Each T150 was suspended with 10-15 mL of medium, centrifuged at 800 rpm for 5 minutes, resuspended in 10 mL of medium, and 1 mL of cell resuspension was aspirated and counted with Vi-cell;

4) Dilute OX1 cells to 5×105/mL with OX2 cells to 4×105/mL, and add the diluted cells to 384 plates (Greiner. 781946) with a lance (50 μL/well, OX1 cells 25000 cells/well). , OX2 cells 20000 cells / well). The cell plates were placed in a 37 ° C, 5% CO 2 incubator overnight. b) Compound loading:

1) The compound was diluted to 20 mM in DMSO, diluted 3 fold, 8 gradients, double duplicate wells, and added to the compound plate using an Echo liquid handler. Then add 20 μL of buffer to ensure a final DMSO concentration of 0.1%; c) FLIPR experiment:

1) Wash the cell culture medium in 384 plates with a vacuum pump, add 30 μL of Fluo4AM fluorescent dye, incubate for 1 hour at 37 ° C in a 5% CO 2 incubator, and equilibrate for 10 minutes at room temperature.

2) EC50 test: Manually dilute Orexin A on ice, 3 fold dilution, 8 gradients, double replicate wells. A DMSO plate was prepared to give a DMSO concentration of 0.5%. The cell plate, the Orexin A plate, and the DMSO plate were placed in the FLIPR, respectively, and the fluorescence values were read.

3) Calculate the EC70 value by the EC50 value of Orexin A, prepare a 5 × EC70 solution, add it to the 384 compound plate with a lance, and place it on ice for storage.

4) In the FLIPR, put the compound plate, 5 × EC70 plate, cell plate, FLIPR gun head, run the program, and read the fluorescence value. d) Analytical data: The data were analyzed using Prism 5.0 to calculate the IC50 value of the compound.

The experimental results are shown in Table 1:

Conclusion: As can be seen from Table 1, the exemplified compounds of the present invention have significant inhibitory effects on OX1 and OX2 GPCR receptors, with some of the exemplified compounds having more excellent activity than the positive controls. Furthermore, it was found that for some of the exemplified compounds, the difference in stereoconfiguration has a greater effect on the inhibition of OX1 and OX2 GPCR receptors.

no.

no.

no.

Claims (22)

a compound of the formula (I) or a pharmaceutically acceptable salt thereof, (I) wherein A is selected from a selectively substituted 3 to 12 membered cyclic hydrocarbon group or a heterocycloalkyl group or a cycloalkyl group, and the cycloalkyl or heterocycloalkyl or cycloalkyl group may be monocyclic or bicyclic, In the form of a spiro, cyclo or fused ring, the substituent is selected from the group consisting of F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or hydroxy or amine or unsubstituted C _1-6 alkyl or heteroalkyl or alkylene or heteroalkano, halogenated or hydroxy or amine or unsubstituted C _3-8 cyclo or heterocyclyl or cyclohetero or hetero The cyclohetero, heteroatoms or heteroatoms are each independently selected from C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O)O, C _{1- 6} -alkane or C _{3-8 cycloalkane or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C=O, C =S, S(=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of being chemically stable; B is selected from C(=O), S (=O) or S(=O) ₂ ; X is selected from (CH ₂ ) _r1 (U) _r2 (CH ₂ ) _r3 which is optionally substituted, and the substituent is selected from the group consisting of F, Cl, Br, I, CN, = O, = S, OH, SH, NH 2, halo or a substituted or hydroxyalkyl A substituted or unsubstituted alkyl or substituted C _1-6 alkyl or heteroalkyl group or heteroaryl group heteroalkyl heteroaryl, halo, or a substituted or hydroxyalkyl substituted amine a substituted or unsubstituted C _3-8 cycloalkyl group or heterocyclic group, or Cyclohetero or heterocyclic heterocycles, heteroatoms or heteroatoms, each independently selected from _C1-6 alkane or _{C3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O) O, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C=O, C=S, S(=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of being chemically stable; r ₁ , r ₃ Each is independently selected from 0, 1 or 2, r _{2 is} selected from 0 or 1, and r ₁ , r ₂ and r ₃ are 0 at the same time, and X is a single bond which only serves as a linking; U is selected from halogen or hydroxy or Amine or unsubstituted CH ₂ , C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O)O, C _1-6 alkane or C _{3-8 cycloalkyl or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C=O, C=S, S (= O) and / or S (= O) _2, under the premise that the number of substituents on chemically stable implementation is arbitrary; D, L min Is independently selected from optionally substituted CH _2, substituents are selected from F, Cl, Br, I, CN, = O, = S, OH, SH, NH 2, halo or a substituted or hydroxyalkyl substituted or amine Substituted C _1-6 alkyl or heteroalkyl or alkylene or heteroalkano, halogenated or hydroxy or amine or unsubstituted C _3-8 cyclo or heterocyclyl or cyclohetero Or a heterocyclic hetero group, a hetero atom or a hetero atom group, respectively, independently selected from C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O)O, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C=O , C=S, S(=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of being chemically stable; T is selected from C or only connected a single bond of action, when T is selected from a single bond, R ₂ , R ₃ are absent; M is selected from C(Y)(R _1a ), where Q is selected from C(R _1b )(R _1c ), or, M It is selected from C(R _1b )(R _1c ), where Q is selected from C(Y)(R _1a ); Y is selected from -(CH ₂ ) _r4 (G) _r5 (CH ₂ ) _r6 -Y ₁ , Y ₁ a structure selected from -OE or (Y ₂ ), (Y ₂ ) G is selected from halogenated or hydroxy or amine or unsubstituted CH ₂ , C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted NH, O, S, S ( =O), S(=O) ₂ , C(=O) or C(=S), the number of substituents is arbitrary under the premise of chemically stable implementation; r ₄ and r ₆ are each independently selected from 0 , 1 or 2, r _{5 is} selected from 0 or 1, and r ₄ , r ₅ and r ₆ are 0 at the same time, and the corresponding structure is a single bond which only serves as a linking; E is selected from a 5 to 6 membered ring which is selectively substituted a hydrocarbyl or heterocyclic group, the substituent being selected from the group consisting of F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or hydroxy or amine or unsubstituted C _1-6 Alkyl or heteroalkyl or alkyl or heteroalkanyl, halo or hydroxy or amine or unsubstituted C _3-8 cyclo or heterocyclyl or cyclohetero or heterocyclo, hetero The atom or heteroatom group is independently selected from C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O)O, C _1-6 alkane or C _{3-8 cycloalkyl or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C=O, C=S, S ( =O) and / or S (=O) ₂ , the number of substituents, heteroatoms or heteroatoms is chemically It is arbitrary under the premise of stable realization; Y _2a , Y _2b , Y _2c , Y _2d , Y _2e , Y _2f , Y _{2g are} selected from selectively substituted CH ₂ , CH, NH, or selected from N, O , S, S(=O), S(=O) ₂ , C(=O) or C(=S), and Y _2a , Y _2b , Y _2c , Y _2d , Y _2e , Y _2f , Y _2g One is optionally substituted CH, CH ₂ or NH, the substituent is selected from the group consisting of F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or hydroxy or amine a substituted or unsubstituted C _1-6 alkyl or heteroalkyl or alkylene or heteroalkanoyl, halo or hydroxy or an amine or unsubstituted C _3-8 cyclo or heterocyclyl or Cyclohetero or heterocyclic heterocycles, heteroatoms or heteroatoms, each independently selected from _C1-6 alkane or _{C3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O) O, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C=O, C=S, S(=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of being chemically stable; Represents a single bond or a double bond; R _1a , R _1b , R _1c , R ₂ , R ₃ are each independently selected from H, F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or hydroxy or amine or unsubstituted C _1-6 alkyl or heteroalkyl or alkino or heteroalkano, halogenated or hydroxy or amine or unsubstituted C _{3 8} acyclic or heterocyclic or cyclohetero or heterocyclic hetero, heteroatoms or heteroatoms independently selected from C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C (=O) NH, C(=O)O, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} Unsubstituted C=NH, C=O, C=S, S(=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is chemically stable Optionally, or R ₂ , R _{3 are} selectively joined to form a ring; and the compound or a pharmaceutically acceptable salt thereof comprises one or more palmitic centers. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is selected from the structural unit represented by formula (A ₁ ) or (A ₂ ): (A ₁ ) (A ₂ ) wherein Z ₁ , Z ₂ , Z ₃ , Z ₄ , Z ₅ are each independently selected from halo or hydroxy or amine or unsubstituted CH or CH ₂ , or C _1-6 alkane Or C _{3-8 cycloalkane or} unsubstituted C(=O)NH or NH, C=N, N, O, S, S(=O), S(=O) ₂ , C(=O) O, C (= O) or C (= S), the number of substituents is arbitrary under the premise of chemically stable implementation; V ₁ , V ₂ , V ₃ , V ₄ , V ₅ are each independently selected from halogen Or hydroxy or amine or unsubstituted CH or CH ₂ , C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C(=O)NH or NH, C=N, C , N, O, S, S(=O), S(=O) ₂ , C(=O)O, C(=O) or C(=S), and at least one of V _1-5 is C or N, the number of substituents is arbitrary under the premise of chemically stable implementation; Represents a single bond or a double bond; R ₄ and R ₆ are each independently selected from H, F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or hydroxy or amine Or unsubstituted C _1-6 alkyl or heteroalkyl or alkylene or heteroalkano, halogenated or hydroxy or amine or unsubstituted C _3-8 cyclic or heterocyclic or ring Hetero or heterocyclic hetero groups, heteroatoms or heteroatoms, each independently selected from C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O)O , C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C =O, C=S, S(=O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of chemically stable implementation; R ₅ and R ₇ respectively Independently selected from 5 to 6 membered cycloalkyl or heterocyclic groups which are optionally substituted, the substituents being selected from the group consisting of F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated Or hydroxy or amine or unsubstituted C _1-6 alkyl or heteroalkyl or alkino or heteroalkano, halogenated or hydroxy or amine or unsubstituted C _3-8 cyclic Or a heterocyclic or cyclohetero or heterocyclic hetero group, Hetero atom or group of atoms independently selected from C _1-6 alkyl or C _{3-8 cycloalkyl} substituting _{a substituted or} unsubstituted C (= O) NH, C (= O) O, C 1-6 alkyl or C substituting _{3-8 cycloalkyl or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C=O, C=S, S ( =O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of being chemically stable; n _{4 is} selected from 0, _1, 2, 3, 4; n _{6 is} selected from 0, 1, 2, and 3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein the structural unit Selected from phenyl or pyridyl, It is selected from a furyl group, a thienyl group or a thiazolyl group. The compound of claim 2 or 3, or a pharmaceutically acceptable salt thereof, wherein the formula (A ₂ ) is selected from the structure represented by the formula (A ₂₁ ): (A ₂₁ ) wherein V ₁ , V ₂ , V ₃ , V ₄ , V ₅ , R ₆ , R ₇ , and n _{6 are} as defined in the second item of the patent application. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein A is selected from the structural unit represented by formula ( _A22 ): (A ₂₂ ) wherein R ₆ and R ₇ are as defined in item 2 of the patent application; n _{6a is} selected from 0, 1 or 2. The compound of claim 2, 3, 4, or 5, or a pharmaceutically acceptable salt thereof, wherein the R ₅ or R ₇ is a 5- to 6-membered cycloalkyl or heterocyclic ring. The groups are each independently selected from the group consisting of phenyl, pyridyl, furyl, thienyl, thiazolyl, pyrimidinyl, pyrazolyl, 1,2,3-triazolyl or 1,2,5-triazolyl. The compound of claim 1, wherein the A is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , . The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the formula (Y ₂ ) is selected from the structure represented by the formula (Y ₂₁ ): (Y ₂₁ ) wherein Y _2a , Y _2b , Y _2c , Y _2d , Y _2e , Y _2f , Y _{2g are} as defined in the first item of the patent application. The compound of claim 8 or a pharmaceutically acceptable salt thereof, wherein the formula (Y ₂₁ ) is selected from the structures represented by the formula (Y ₂₂ ) which are optionally substituted: (Y ₂₂ ) wherein the substituent is selected from the group consisting of F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or hydroxy or amine or unsubstituted C _1-6 Alkyl or heteroalkyl or alkyl or heteroalkanyl, halo or hydroxy or amine or unsubstituted C _3-8 cyclo or heterocyclyl or cyclohetero or heterocyclo, hetero The atom or heteroatom group is independently selected from C _1-6 alkane or C _{3-8 cycloalkane or} unsubstituted C(=O)NH, C(=O)O, C _1-6 alkane or C _{3-8 cycloalkyl or} unsubstituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C=NH, C=O, C=S, S ( =O) and/or S(=O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of being chemically stable. The compound of claim 9 or a pharmaceutically acceptable salt thereof, wherein Y is selected from the group consisting of selectively substituted or . The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Y is selected from -CH ₂ -OE or -OE, wherein E is as defined in claim 1 of the scope of the patent application. The compound of claim 1 or 11, or a pharmaceutically acceptable salt thereof, wherein E is selected from the structural unit represented by the formula (E _a ): (E _a ) wherein E ₁ , E ₂ , E ₃ , and E ₄ are each independently selected from halo or hydroxy or amine or unsubstituted CH, N; and R ₈ and R ₉ are each independently selected from H, F, Cl, Br, I, CN, =O, =S, OH, SH, NH ₂ , halogenated or hydroxy or amine or unsubstituted C _1-6 alkyl or heteroalkyl or alkane Hetero or heteroalkanyl, halo or hydroxy or amine or unsubstituted C _3-8 cyclo or heterocyclyl or cyclohetero or heterocyclic heterocycle, heteroatoms or heteroatoms independently selected from C _1-6 alkyl or C _{3-8 cycloalkyl} substituting _{a substituted or} unsubstituted C (= O) NH, C (= O) O, C 1-6 alkoxy or C _{3-8 cycloalkyl} substituting _or not _substituting Substituted NH, O, S, C _1-6 alken or C _{3-8 cycloalkane or} unsubstituted C = NH, C = O, C = S, S (= O) and / or S ( =O) ₂ , the number of substituents, heteroatoms or heteroatoms is arbitrary under the premise of being chemically stable. The compound of claim 12 or a pharmaceutically acceptable salt thereof, wherein the structural unit It is a phenyl or pyridyl group, or a thienyl or furyl group. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein Y is selected from the group consisting of: . The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein U, X, and G are each independently selected from NH or NC _1-6 alkyl. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R _1a , R _1b , R _1c are each independently selected from H, methyl or fluoro. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R ₂ and R ₃ are each independently selected from H, methyl, fluoro or cyclopropyl. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R ₂ and R _{3 are} bonded to a 3- to 8-membered cycloalkyl group; specifically, R ₂ and R _{3 are} bonded to form a cyclopropyl group. The compound of any one of claims 1 to 18, wherein the C _1-6 alkyl group is selected from the group consisting of methyl, ethyl, propyl, butyl, or a pharmaceutically acceptable salt thereof. A pentyl group, a hexyl group, wherein the propyl group, the butyl group, the pentyl group, and the hexyl group are selectively cyclized or partially cyclized. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the following structure: , , , , , , , , , , , , , , , , , , . A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. A compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 21, in the preparation of a treatment for insomnia, chronic obstruction Use in drugs for pulmonary disease, obstructive sleep apnea, lethargy, anxiety, coercion, panic, nicotine dependence, or eating disorders.